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EPIGRAPH
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-- Henry David Thoreau (1817 – 1862)
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ABSTRACT

THE REGULATION OF DNA METHYLATION IN MAMMALIAN

DEVELOPMENT AND CANCER

Jaime Nicolas Veland, B.S.

Advisory Professor: Taiping Chen, Ph.D.

DNA methylation is an essential epigenetic modification in mammals, as it plays important
regulatory roles in multiple biological processes, such as gene transcription, maintenance of
chromosomal structure and genomic stability, genomic imprinting, retrotransposon silencing, and Xchromosome inactivation. Dysregulation of DNA methylation is associated with various human diseases.
For example, cancer cells usually show global hypomethylation and regional hypermenthylation, which
have been implicated in genomic instability and tumor suppressor silencing, respectively. Although great
progress has been made in elucidating the biological functions of DNA methylation over the last several
decades, how DNA methylation patterns and levels are regulated and dysregulated is not well
understood. This dissertation focuses on the molecular mechanisms involved in the regulation of DNA
methylation during mammalian development and in cancer. Using mouse embryonic stem cells
(mESCs), an ideal model system for studying DNA methylation, I have discovered novel regulatory
mechanisms that play important roles in de novo and maintenance DNA methylation. In one project, I
show that Dnmt3L, a key regulator of de novo methylation, facilitates Dnmt3a-mediated methylation by
stabilizing Dnmt3a2, the major Dnmt3a isoform in mESCs, thus uncovering a new role for Dnmt3L and
providing a plausible explanation for the functional specificity of Dnmt3L. In a separate project, I
viii

demonstrate that PRMT6, an arginine methyltransferase responsible for asymmetric dimethylation of
histone H3 arginine 2 (H3R2me2a), negatively regulates maintenance DNA methylation by impairing
the recruitment of the Dnmt1-Uhrf1 complex to chromatin, thereby identifying a novel crosstalk between
histone arginine methylation and DNA methylation. Moreover, I show that PRMT6 upregulation
contributes to global DNA hypomethylation in cancer. Lastly, my work results in the identification of an
intestine-specific Dnmt1 protein product that originates from a proteolytic cleavage event, which could
shed light on the regulation of DNA methylation in intestinal stem cells (ISCs). In summary, the research
work in this dissertation advances our understanding of the regulatory network that controls DNA
methylation changes in normal developmental processes and pathological conditions.
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CHAPTER 1 : INTRODUCTION

Part of this chapter is based upon: Veland N & Chen T. (2017) Mechanisms of DNA Methylation and
Demethylation during Mammalian Development. In Handbook of Epigenetics, 2nd Edition. (ed.
Tollefsbol T.), Elsevier Inc. Academic Press, pp11-24.

Table 1 was adapted from the original version used in: Nicholson TB, Veland N, Chen T. (2015) Writers,
Readers, and Erasers of Epigenetic Marks. In Epigenetic Cancer Therapy. (ed. Gray S.G.), Elsevier Inc.
Academic Press, pp. 31-66.

Used with permission of Elsevier.
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1.1 OVERVIEW OF DNA METHYLATION

DNA methylation, the covalent addition of a methyl group to the fifth position of cytosine (i.e.
5-methylcytosine, 5mC), was initially discovered as epi-cytosine by Rollin D. Hotchkiss more than 60
years ago (1). Subsequent studies revealed that DNA methylation is the most common form of DNA
modification, which plays important roles in the regulation of chromatin structure and gene expression.
DNA methylation is present in various organisms including many animals, plants and fungi. In
mammals, DNA methylation mostly occurs in the context of CpG dinucleotides, with 60-80% of all
CpGs in the genome being methylated, although non-CpG (i.e. CpA, CpT or CpC) methylation is
abundant in specific tissues and cell types, including embryonic stem cells (ESCs), oocytes, and brain
tissue (2). DNA methylation is essential for mammalian development and plays key roles in multiple
biological processes such as genomic imprinting, X-chromosome inactivation, and transposon silencing
(3). Consistent with its pleiotropic roles, DNA methylation patterns are altered in pathological
conditions.

For example,

cancer cells

usually

exhibit

global

hypomethylation and

local

hypermethylation, which contribute to genomic instability and tumor suppressor silencing, respectively
(4).
5mC is not randomly distributed in the genome. In general, repetitive DNA sequences, including
transposable elements and centromeric and pericentric satellite DNA, are heavily methylated. In contrast,
CpG islands (CGIs, 1-2 kilobases of GC-rich regions) present in gene promoters are usually depleted of
DNA methylation, with some exceptions. For example, CpGs on the inactive X chromosome in female
cells are hypermethylated, and CpGs in imprinting control regions (ICRs) exhibit allele-specific
methylation. On the other hand, gene bodies, especially exons, are often highly methylated. Unlike
promoter methylation, which correlates with gene silencing, gene body methylation is often associated
with transcriptional activity (5).
In 1975, Holliday and Pugh and Riggs proposed that DNA methylation could be important for
cellular memory by serving as a heritable epigenetic mark through cell division. Based on the
complementarity of CpG/CpG dyads, they reasoned that methylated CpG sites could be replicated semi2

conservatively during DNA replication (6, 7). The theory would predict the existence of two DNA
methyltransferase activities: de novo methyltransferase(s) methylate unmodified DNA to establish DNA
methylation patterns, and maintenance methyltransferase(s) methylate newly formed hemi-methylated
CpG sites during DNA replication to maintain the patterns (Figure 1). The hypothesis was subsequently
validated, to a large extent, by the identification of DNA methyltransferases with distinct expression
patterns, biochemical properties, and biological functions (8).
DNA methylation patterns and levels are determined by the opposing actions of the methylation
and demethylation machineries. The methylation machinery includes DNA methyltransferases
(DNMTs), which catalyze the transfer of a methyl group from the methyl donor S-adenosyl-Lmethionine (AdoMet or SAM) to the C-5 position of cytosines. There are four active DNMTs in
mammals: DNMT1 is mainly responsible for maintaining DNA methylation patterns during DNA
replication, whereas DNMT3A and DNMT3B function primarily as de novo methyltransferases that
establish DNA methylation patterns (8). Recently, a new family member named DNMT3C is been found
exclusively in rodents, where it plays a specific role in de novo methylation at retrotransposons during
spermatogenesis (9). DNMT2, a protein with conserved DNMT catalytic motifs, turned out to be an
aspartic acid tRNA methyltransferase and has been renamed tRNA aspartic acid (D) methyltransferase 1
(TRDM1) (10). From a chemical perspective, DNA methylation is considered a relatively stable
modification. However, global demethylation occurs in pre-implantation embryos and primordial germ
cells (PGCs), and locus-specific demethylation takes place during cellular differentiation. DNA
demethylation can be achieved by replication-dependent “passive” dilution of 5mC and replicationindependent “active” processes (11, 12). Great progress has been made in understanding the mechanisms
of demethylation over the last several years, thanks to the discovery that the ten-eleven translocation
(TET) family of proteins - TET1, TET2, and TET3 - function as 5mC dioxygenases that convert 5mC to
5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) (13-16).
There is compelling evidence that 5hmC, 5fC, and 5caC serve as intermediates for DNA demethylation
(11, 12).
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Figure 1: Overview of mechanisms of DNA methylation.
During early development, de novo methylation adds methyl groups to specific CpG sites on both DNA
strands (resulting in symmetric CpG methylation) and establishes DNA methylation patterns. After each
round of DNA replication, the methylated CpG sites become hemi-methylated, as the newly replicated
daughter DNA strand is unmethylated. Maintenance methylation recognizes hemi-methylated CpG sites
and “copies” the DNA methylation pattern of the parental strand onto the daughter strand. Open and
black filled circles indicate unmethylated and methylated CpG dinucleotides, respectively. U,
unmethylated DNA; M, methylated DNA; H, hemi-methyalted DNA. The enzymes and their major
accessary factors involved at different steps of DNA methylation are indicated.
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1.2 DE NOVO DNA METHYLATION DURING MAMMALIAN DEVELOPMENT

After fertilization, both the maternal and paternal genomes undergo global DNA demethylation
during preimplantation development. As a result, DNA methylation marks inherited from gametes are
largely erased by the blastocyst stage, with the exception of those in ICRs and some retrotransposons.
After implantation, a wave of de novo methylation occurs in the epiblast to establish the initial pattern of
DNA methylation (Figure 1) (17). DNA methylation shows further changes during cellular
differentiation, and the patterns are then stably maintained in a lineage-specific manner after successive
cell divisions. Similar epigenetic reprogramming events also take place during gametogenesis, including
global demethylation in PGCs. Subsequently, a new round of de novo DNA methylation takes place in
germ cells, which have already passed sex-determination, resulting in different methylation patterns in
male and female gametes (sperm and egg) (3, 17). De novo methylation is mediated by DNMT3A and
DNMT3B. A third member of the DNMT3 family, DNMT3-like (DNMT3L), has no catalytic activity,
but is an important regulator of de novo methylation (Figure 2) (8).

5

Figure 2: Schematic diagram of major proteins involved in DNA methylation.
A. Protein domain architecture of mouse DNA methyltransferases (DNMTs). The DNMT1 and DNMT3
families of proteins share conserved catalytic motifs (I-X) in their C-terminal catalytic domains.
DNMT3L lacks catalytic activity because some essential motifs are missing or mutated. The N-terminal
regions of DNMT1 and DNMT3 proteins have little sequence similarity, with distinct domains that
contribute to their functional specificities. DMAP1: DNA methyltransferase associated protein 1; PBD:
PCNA-binding domain; NLS: nuclear localization sequence; RFTS: replication foci targeting sequence;
UIM: ubiquitin interacting motif; CXXC: cysteine-rich motif; BAH: bromo-adjacent homology; GK:
glycine/lysine-rich linker; I-X: DNA methyltransferase conserved catalytic motifs; PWWP: prolinetryptophan-tryptophan-proline; ADD: ATRX-DNMT3-DNMT3L. The start site of the DNMT1o isoform
is indicated. Locations of the most common alternatively spliced exons (exons 10, 11, 20, 21, 22) in
DNMT3B are also indicated. B. Protein domain architecture of mouse UHRF1. UBL: ubiquitin-like
domain; TTD: tandem tudor domain; PHD: plant homeodomain; SRA: SET and RING associated;
RING: Really Interesting New Gene.
6

DNMT3A and DNMT3B
The DNMT3A and DNMT3B genes were initially identified by searching an expressed sequence
tag (EST) database using bacterial type II cytosine-5 methyltransferase sequences as queries. Their
protein products have a similar structural organization, including a C-terminal catalytic domain that
contains sequence motifs characteristic of all DNA methyltransferases (prokaryotic and eukaryotic) and
an N-terminal regulatory domain that is distinct from that of DNMT1 (Figure 2) (18). The N-terminal
regions of DNMT3A/3B contain a variable region (not conserved between DNMT3A and DNMT3B),
followed by two conserved domains implicated in chromatin binding. The PWWP domain, an ~150residue domain with a conserved proline-tryptophan-tryptophan-proline (PWWP) motif, is necessary for
heterochromatin targeting and mediates binding to trimethylated lysine 36 of histone H3 (H3K36me3)
marks (19-21). The ADD (ATRX-DNMT3-DNMT3L) domain, composed of two C4-type zinc fingers
(GATA binding protein 1 (GATA1) and plant homeodomain (PHD)-type), interacts with the N-terminal
tail of histone H3 with unmodified lysine 4 (H3K4) (22, 23). Recent structural studies revealed that the
ADD domain of DNMT3A interacts with its catalytic domain and blocks its DNA-binding affinity,
resulting in autoinhibition. Unmodified histone H3 tail (but not H3 tail with H3K4me3) can disrupt the
interaction between the ADD and the catalytic domains, leading to DNMT3A activation (24). These
findings indicate that DNMT3A and DNMT3B act as both “writers” and “readers” of epigenetic marks
and that their activities and specificities are regulated by specific histone modifications.
The conclusion that DNMT3A and DNMT3B function primarily as de novo methyltransferases
is based on several lines of evidence. First, DNMT3A and DNMT3B expression correlates with de novo
methylation during development. Specifically, DNMT3A and DNMT3B are highly expressed in early
embryos (as well as ESCs) and developing germ cells, and their expression is significantly
downregulated in somatic cells and when ESCs are differentiated (18). In ESCs, DNMT3A transcription
is mostly driven by an internal promoter, resulting in a shorter isoform known as DNMT3A2, which
lacks the N-terminal 219 (mouse) or 223 (human) amino acids of full-length DNMT3A1 (Figure 2).
DNMT3A2 expression decreases with ESC differentiation and is replaced by the DNMT3A1 isoform,
which is ubiquitously expressed at low levels in most somatic tissues (25). DNMT3B produces multiple
7

alternatively spliced isoforms (~30 reported to date), many of which lack catalytic activity but may play
regulatory roles in DNA methylation (26). In ESCs, the full-length isoform DNMT3B1, a catalytically
active form, is the predominant product, and other isoforms, including the inactive DNMT3B6, are also
expressed. In most somatic cells, DNMT3B expression is low, usually with both active (e.g. DNMT3B2)
and inactive (e.g. DNMT3B3) isoforms (18, 25).
Second, biochemical studies indicate that DNMT3A and DNMT3B behave as de novo
methyltransferases do. In particular, recombinant DNMT3A and DNMT3B proteins show no preference
for hemi-methylated DNA over unmethylated DNA in vitro, unlike DNMT1, which preferentially
methylates hemi-methylated DNA (18, 27). Furthermore, in vitro and in vivo target analyses indicate that
DNMT3A and DNMT3B could methylate cytosines at non-CpG sites such as CpA and CpT, albeit with
lower efficiency compared to CpG methylation (28). Non-CpG methylation, which cannot be maintained
during DNA replication, is mediated by de novo methyltransferases.
Third, genetic studies provide definitive evidence for the involvement of DNMT3A and
DNMT3B in de novo DNA methylation. Targeted disruption of both DNMT3A and DNMT3B blocks de
novo methylation in mouse ESCs (mESCs) and early embryos, but has no effect on the maintenance of
methylation at imprinted loci (29). Moreover, DNMT3A and DNMT3B cause de novo methylation when
overexpressed in mammalian cells or ectopically expressed in transgenic flies or budding yeast (30-33).
While DNMT3A and DNMT3B methylate many genomic loci redundantly, they also have preferred and
distinct targets. For example, DNMT3A is more efficient than DNMT3B in methylating major satellite
repeats at pericentric heterochromatin, whereas DNMT3B preferentially methylates minor satellite
repeats in centromeric regions (32). Characterization of DNMT3A and DNMT3B knockout (KO) mice
suggest that these enzymes play distinct roles in developmental processes. DNMT3A KO mice develop to
term and show no overt defects at birth, but die at ~4 weeks of age. In contrast, disruption of DNMT3B
leads to embryonic lethality at ~E12.5, with multiple developmental defects. DNMT3A/3B double KO
(DKO) embryos exhibit more severe defects and die earlier (before E11.5) than DNMT3B KO embryos
(29). DNA methylation analysis of E9.5 embryos indicate that DNMT3B is largely responsible for
methylation of germline-specific genes, pluripotency genes, and many developmental genes and
8

DNMT3A and DNMT3B redundantly methylate some specific genes such as Brdt, Dpep3, Cytip, and
Crygd (34). Conditional gene KO studies indicate that DNMT3A, but not DNMT3B, is essential for de
novo methylation during gametogenesis, including the establishment of DNA methylation imprints (35).
Indeed, immunofluorescence experiments show abundant expression of DNMT3A, but not DNMT3B, in
fully grown oocytes (36).
Consistent with their important roles in developmental processes in mice, DNMT3A and
DNMT3B mutations are associated with human diseases (37). Somatic DNMT3A mutations occur
frequently in acute myeloid leukemia (AML) and other hematologic malignancies (37). Many DNMT3A
mutations have been identified, with the majority (>50%) of cases affecting Arg882 (R882) in the
catalytic domain. Although almost all reported DNMT3A mutations in leukemia occur in only one allele,
there is evidence that DNMT3A R882 mutant proteins have dominant-negative effects by interacting
with wild-type DNMT3A to form functionally deficient complexes (38). DNMT3A mutations are also
associated with Tatton Brown Rahman syndrome, an overgrowth disorder (37). Hypomorphic DNMT3B
mutations account for ~50% of cases with ICF (Immunodeficiency, Centromeric instability, and Facial
anomalies) syndrome, a rare recessive autosomal disorder characterized by hypomethylation of special
genomic regions (most notably classical satellites 2 and 3 repeats) and chromosomal defects in
lymphocytes and antibody deficiency, as well as facial dysmorphism, failure to thrive, and mental
retardation (37). Several other ICF genes – ZBTB24 (zinc-finger- and BTB domain-containing 24),
CDCA7 (cell division cycle associated 7), and HELLS (helicase, lymphoid-specific) – have also been
identified (39, 40). HELLS (also known as LSH), a DNA helicase involved in chromatin remodeling, has
been shown to regulate DNA methylation by affecting DNMT3B targeting to chromatin (41). However,
little is known about the biological functions of ZBTB24 and CDCA7 and, in particular, their links to
DNA methylation.

DNMT3L
DNMT3L was originally identified by sequence database analysis. The protein product contains
an ADD domain, but not a PWWP domain, in the N-terminal region. Its C-terminal region shares
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sequence homology with the catalytic domains of DNMT3A and DNMT3B, but lacks some sequence
motifs essential for catalytic activity, including those required for AdoMet (methyl donor) binding
(Figure 2) (8).
Although DNMT3L has no methyltransferase activity, biochemical and genetic evidence
suggests that it is an important regulator of de novo methylation. DNMT3L interacts with DNMT3A and
DNMT3B and significantly enhances their catalytic activity (42). Crystallographic studies reveal that the
C-terminal region of DNMT3L directly interacts with the catalytic domain of DNMT3A, and the
DNMT3A/3L dimer further dimerizes through DNMT3A-DNMT3A interaction, forming a tetramer with
two active sites (43). Biochemical and structural data also indicate that the ADD domain of DNMT3L
binds to the N-terminal tail of histone H3, specifically recognizing unmodified lysine 4 (H3K4),
suggesting that DNMT3L plays a role in determining the specificity of de novo methylation (22). The
expression pattern of DNMT3L during development is similar to that of DNMT3A and DNMT3B, with
high expression in developing germ cells, early embryos and ESCs and low expression in most somatic
tissues (42). DNMT3L KO mice are viable and grossly normal, suggesting that zygotic DNMT3L is not
essential for development. However, both male and female KO mice fail to reproduce (42, 44). DNMT3L
KO males have reduced testis size and are sterile, as they are unable to produce mature sperm
(azoospermia). The spermatogenesis defect is due to loss of DNA methylation in germ cells, which
results in reactivation of retrotransposons, inducing genomic instability, meiotic catastrophe, and
ultimately apoptosis (45). On the other hand, DNMT3L KO females produce oocytes and are able to
conceive, but their embryos die by mid-gestation due to failure to establish DNA methylation imprints in
oocytes (42, 44). These studies suggest that DNMT3L is a critical accessory factor for DNMT3A for de
novo methylation during gametogenesis. Indeed, the phenotype of DNMT3L KO mice is almost identical
to that of mice with conditional DNMT3A deletion in germ cells (35).
The genetic studies described above suggest that DNMT3L is functionally more important for
DNMT3A than for DNMT3B in vivo, contrary to biochemical evidence that DNMT3L is equally
efficient in stimulating the catalytic activities of both DNMT3A and DNMT3B in vitro. Little is known
about what determines the functional specificity of DNMT3L. In contrast to the strong evidence that
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supports the essential role for DNMT3L in de novo methylation during gametogenesis, its role in mESCs
is poorly understood and controversial. It has been shown that Dnmt3L is required to silence ectopic
integrated retroviral DNA in mESCs, and that Dnmt3L deficiency decreases their DNA methylation over
time in culture (46, 47). Moreover, Dnmt3L heterochromatin foci localization depends on the presence of
Dnmt3a2, but not on Dnmt3a or Dnmt3b, probably due to the specific interaction between Dnmt3L and
Dnmt3a2 in mESCs (48). Together, these studies suggest that Dnmt3L is a positive regulator of de novo
DNA methylation in mESCs. However, a recent report by Neri and colleagues suggests dual roles for
Dnmt3L, both as a negative and positive regulator of DNA methylation, depending on genomic regions,
in mESCs (49). In Chapter 3 of this dissertation, I aim to clarify the role of Dnmt3L and elucidate the
molecular mechanism involved in de novo DNA methylation using Dnmt3L-deficienct mESCs.

1.3 MAINTENANCE DNA METHYLATION DURING MAMMALIAN DEVELOPMENT

Once DNA methylation patterns are established during early embryogenesis, they are maintained
in somatic cells in a cell type-specific manner. During each round of DNA replication, DNA becomes
hemi-methylated, as only CpGs on the parental strand remain methylated while CpGs on the newly
replicated daughter strand are unmethylated. To re-establish the symmetry of CpG methylation and keep
the specificity, the maintenance DNA methyltransferase activity recognizes hemi-methylated CpGs and
methylates the corresponding CpGs on the daughter strand. Biochemical, cellular, and genetic evidence
suggests that DNMT1 is the major maintenance methyltransferase (8). In addition, a multi-domain
protein, UHRF1 (ubiquitin-like with PHD and RING finger domains 1), is essential for directing
DNMT1 to DNA replication sites (50, 51).

DNMT1
Mouse DNMT1, the first mammalian DNA methyltransferase gene identified (52), has several
transcription start sites and produces two major protein products. Transcripts initiated within a somatic
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cell-specific exon encode the full-length DNMT1 protein that is expressed in somatic cell types, whereas
transcripts initiated within an oocyte-specific exon utilize a downstream AUG as the translation initiation
codon, resulting in the DNMT1o isoform that lacks the N-terminal 118 amino acids of full-length
DNMT1 (Figure 2) (8). Both isoforms are equally functional in maintaining DNA methylation, although
DNMT1o is more stable than DNMT1 (53).
DNMT1 has an N-terminal regulatory domain and a C-terminal catalytic domain (Figure 2).
While all DNMTs contain highly conserved DNA methyltransferase motifs in their catalytic domains,
the DNMT1 and DNMT3 families show little sequence similarity in their regulatory domains. There are
several unique domains in the N-terminal region of DNMT1 that confer its functional difference from
DNMT3 enzymes. A region at the very N terminus mediates the interaction between DNMT1 and DNA
methyltransferase associated protein 1 (DMAP1), a protein implicated in histone acetylation and ATM
signaling. The DMAP1-interaction domain is absent in the more stable DNMT1o isoform (53),
suggesting that this domain or the interaction between DNMT1 and DMAP1 may be involved in
regulating DNMT1 stability. The DMAP1-interaction domain is followed by a proliferating cell nuclear
antigen (PCNA) binding domain (PBD), which is required for the interaction with the DNA replication
machinery, and a nuclear localization signal (NLS) (8). DNMT1 also contains a motif originally named
as the replication foci-targeting sequence (RFTS). Recent evidence indicates that RFTS contains a
ubiquitin-interacting motif (UIM) that recognizes ubiquitinated histone H3 at lysine 18 (H3K18ub), a
histone modification that serves as a docking site for DNMT1 targeting to replication foci (54).
Structural data obtained recently suggests that the RFTS domain also plays an autoinhibitory role in the
regulation of DNMT1 activity by binding to the catalytic domain and blocks the catalytic center (55).
Additionally, DNMT1 contains a CXXC domain, a cysteine-rich motif that binds unmethylated CpGs,
and a pair of bromo-adjacent homology (BAH) domains, BAH1 and BAH2, with their role remaining
unknown (8).
Biochemical assays reveal that DNMT1 preferentially methylates hemi-methylated CpG
dinucleotides, although it is capable of methylating unmethylated substrates as well (27). DNMT1 is
constitutively expressed in proliferating cells. During S phase, DNMT1 is upregulated and associates
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with the replication foci, suggesting that DNMT1-mediated methylation is coupled to DNA replication
(56). Genetic inactivation of DNMT1 in mESCs results in global loss of DNA methylation, but does not
affect de novo methylation of integrated provirus DNA (57, 58). Taken together, these results suggest
that DNMT1 functions primarily as a maintenance methyltransferase.
DNA methylation is dispensable in undifferentiated mESCs, as DNMT1 KO, DNMT3A/3B DKO,
and DNMT1/3A/3B triple KO (TKO) mESCs show no defects in viability and proliferation, but these
cells die when induced to differentiate (29, 32, 58-60). A recent study shows that human ESCs (hESCs)
require DNMT1, but not DNMT3A and DNMT3B, for survival (61). mESCs and hESCs represent
different pluripotent states, with hESCs resembling the more mature epiblast state, which may explain
the sensitivity of hESCs to hypomethylation. DNMT1 is also required for the survival of mouse
embryonic fibroblasts (MEFs) and the human colorectal cancer cell HCT116 (62, 63). These findings
suggest crucial roles for DNMT1 in cellular differentiation and in the viability of differentiated cells.
Consistent with this notion, complete inactivation of DNMT1 results in the arrest of mouse embryonic
development around E9.5, when the embryo is in the process of differentiating into the three germ layers
(58). In human, missense DNMT1 mutations in the RFTS of the N-terminal regulatory domain, which
likely result in hypomorphic alleles, have been identified in two related neurodegenerative disorders,
hereditary sensory and autonomic neuropathy with dementia and hearing loss type IE (HSAN IE) and
autosomal dominant cerebellar ataxia, deafness and narcolepsy (ADCA-DN) (37). While the
mechanisms by which these mutations lead to the disease phenotypes are unknown, changes in DNA
methylation and gene expression likely play an important role.

UHRF1
UHRF1, also known as nuclear protein of ~95-kDa (NP95 in mouse) and inverted CCAAT boxbinding protein (ICBP90 in human), is a multi-domain protein. Genetic studies demonstrate that UHRF1
is essential for maintaining DNA methylation. Similar to the phenotype of DNMT1 deficiency,
disruption of UHRF1 leads to embryonic lethality and global DNA hypomethylation (50, 51, 64).
Cellular studies also suggest functional interactions between DNMT1 and UHRF1. Both proteins are
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enriched at DNA replication foci during the S phase in normal cells, but DNMT1 fails to localize to these
foci in UHRF1 KO cells (50, 51). These findings indicate that UHRF1 is a critical regulator of
maintenance methylation by directing DNMT1 to hemi-methylated CpG sites.
UHRF1 has five conserved domains: a ubiquitin-like domain (UBL), a tandem tudor domain
(TTD), a plant homeodomain (PHD), a SET and RING associated (SRA) domain, and a Really
Interesting New Gene (RING) domain (Figure 2). The mechanisms by which UHRF1 controls DNMT1
localization and DNA methylation are complex, and all the conserved domains, with the exception of
UBL, have been implicated. UHRF1 interacts with DNMT1 and likely mediates its recruitment to
chromatin, as the TTD and PHD of UHRF1 act in combination to recognize the trimethylated lysine 9 of
histone H3 (H3K9me3) mark, and additionally, the PHD finger binds to unmodified arginine 2 of histone
H3 (H3R2) (65, 66). The SRA domain preferentially binds hemi-methylated DNA and likely plays an
important role in loading DNMT1 onto newly synthesized DNA substrates (50, 51). The RING finger
domain has E3 ubiquitin ligase activity. UHRF1 has been shown to ubiquitinate histone H3 at lysine 18
(H3K18ub) in mammalian cells (54) and at lysine 23 (H3K23ub) using the cell-free system of Xenopus
egg extracts (67). Both studies show that UHRF1-dependent histone H3 ubiquitination is required for
maintenance DNA methylation, suggesting that the H3 ubiquitination mark(s) provides a binding site(s)
for DNMT1 (54, 67). Together, these studies indicate that a complex crosstalk between different histone
modifications takes place in the regulation of maintenance DNA methylation.
The UHRF1 PHD finger specifically recognizes and binds unmodified, but not H3R2methylated, N-terminal tail of H3, which suggests that H3R2 methylation might play a role in the
regulation of maintenance DNA methylation. The role of arginine methylation in the regulation of DNA
methylation is largely unknown. This site is the major substrate of PRMT6, an arginine
methyltransferase responsible for asymmetric dimethylation of H3R2 (H3R2me2a) (68-70). In Chapter
4 of this dissertation, I investigated whether H3R2me2a plays a role in the regulation of maintenance of
DNA methylation by impairing the recruitment of UHRF1 to chromatin.
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1.4 DNA METHYLATION IN CANCER

Cancer is a disease of genetic, as well as epigenetic, abnormalities. The latter is supported by a
great outburst of knowledge in chromatin regulation and its importance to aberrant gene expression in
cancer. This led to the concept of “the cancer epigenome”, which encompasses countless alterations that
are not caused by changes in the DNA sequence (i.e. mutations), and rather consist of covalent
modifications to DNA, RNA and chromatin proteins, including histones and non-histone substrates. The
epigenetics field is rapidly evolving, in part due to technological advances such as next-generation
sequencing techniques, which have been widely applied to identifying the structure and organization of
chromatin, including DNA methylation, and with this has transform our understanding of normal
development and cancer (71).
In normal somatic cells, CGIs associated with gene promoters are usually devoid of DNA
methylation, except in special genomic regions, such as genes located in the inactive X chromosome,
inactive imprinted genes and germ-cell specific genes (5, 72). In contrast, alterations of DNA
methylation patterns are frequently detected in cancer, as tumor cells present loci-specific CpG
hypermethylation or global DNA hypomethylation (4) (Figure 3).
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Figure 3: Alterations of DNA methylation patterns in cancer cells.
A. Typical DNA methylation patterns in normal cells, including high levels of methylation in repetitive
sequences and gene bodies and lack of methylation in CGIs associated with promoter regions. B.
Alterations in DNA methylation patterns frequently observed in cancer cells, including global
hypomethylation and abnormal promoter hypermethylation, which contributes to genomic instability and
tumor suppressor silencing, respectively. Open and black filled circles indicate unmethylated and
methylated CpG dinucleotides, respectively. White boxes labeled with E indicate exons. Black horizontal
thin arrow in Exon 1 indicates transcription, which is blocked in B as indicated by the cross. White
horizontal thick arrow indicates repetitive sequences.
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CpG island DNA hypermethylation
Specific gain of DNA methylation (i.e. DNA hypermethylation) in the CGIs of promoters, which
is associated with transcriptional silencing, is among the most investigated epigenetic alteration in
cancer, as multiple studies showed that most cancer types have high numbers of genes with
hypermethylation, although the numbers vary in a patient-specific manner (4, 71-74). In certain cases,
the affected CGIs control the expression of tumor suppressor genes, and therefore, DNA
hypermethylation acts as an alternative mechanism for gene inactivation leading to tumor suppressor
silencing and loss of function, favoring malignant transformation (4, 72). For example, promoters of
tumor suppressor genes involved in pathways that control cell cycle progression, like Rb, CDKN2A and
p73, or that regulate DNA repair, such as MLH1, BRCA1, MGMT and WRN are found hypermethylated
in different tumor types. Additionally, key genes in cancer biology that are silenced by CGI promoter
hypermethylation include VHL, ER, RARb2, APC, DKK1, GATA4, GATA5, ID4, DAPK, and HOXA9
(71, 72). Moreover, DNA hypermethylation has also been implicated in loss of monoallelic expression of
imprinted genes (i.e. loss of imprinting) at the H19 locus, leading to the activation of the insulin-like
growth factor 2 (IGF2) and initiation of tumor development and progression of colon cancer (75-77).
Genomic studies in tumors revealed that cancer-specific mutations are frequently detected in
genes that regulate DNA methylation, which may lead to DNA hypermethylation. For instance,
mutations in TET2, IDH1 (isocitrate dehydrogenase 1) and IDH2 are found in different types of
leukemias and brain cancer, including gliomas and other types of brain tumors, although they are
mutually exclusive (4, 78, 79). TETs are enzymes that catalyze the oxidation of 5mC into 5hmC in a
reaction dependent on the cofactor a-ketoglutarate (80). Patients with mutations in TET2 are commonly
heterozygous and result in loss of function (79). Similarly, mutations of IDH1 and IDH2 impair their
normal enzymatic functions and result in the abnormal conversion of a-ketoglutarate into 2hydroxyglutarate, a metabolite that inhibits the catalytic activity of TET2 (78). As a consequence,
inhibition of the TET pathway by different mechanisms results in DNA hypermethylation due to the
accumulation of 5mC at specific regions. Interestingly, recent studies indicate that under normal
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conditions, TET proteins reside at the CGIs of active promoters and enhancers and contribute to the
maintenance of their hypomethylated state (81-84), suggesting that upon TET inhibition, these locations
might become rapidly hypermethylated. Consistent with this hypothesis, IDH1 mutations in gliomas
correlate with CpG island DNA hypermethylation phenotype (CIMP), a concept used to classify different
types of cancer (71).
Alternative mechanisms have also been proposed to explain DNA hypermethylation in cancer.
One of them is strictly linked to bivalent promoters, which are those promoters that simultaneously
contain the H3K4me3 active and H3K27me3 repressive marks and are associated with poised
transcriptional state of genes required for ESC differentiation (85). Based on correlations observed in
studies in colon cancer, it has been proposed that an epigenetic switch occurs at these promoters during
tumorigenesis, where expanded population of stem cells undergo replacement of temporal H3K27me3
repression by a more stable silencing mediated by H3K9me3 and DNA methylation (71). However, these
mechanisms require further characterization and validation.

Global DNA hypomethylation
Global loss of DNA methylation (i.e. DNA hypomethylation) was initially observed in human
tumors compared to healthy tissue over 30 years ago (86), with H-ras and K-ras as the first examples of
hypomethylated oncogenes in human cancer samples (87). Early studies comparing primary tumors,
normal tissues and metastatic samples isolated from the same patients showed that DNA
hypomethylation was progressive and correlates with metastatic capacity (86, 88). Subsequent studies
revealed that global DNA hypomethylation is a common feature of cancer cells, where it has been
associated to activation of oncogenes, derepression of retrotransposons and genomic instability (72).
Several lines of evidence suggest the involvement of DNA hypomethylation as an early oncogenic event
that leads to transformation and tumorigenesis. Firstly, treatment with DNA methylation inhibitors has
been shown to convert low-metastatic cancer cell lines to high-metastatic versions, and animals fed with
methyl-deficient diet result in global DNA hypomethylation and formation of liver tumors (89).
Secondly, mice carrying a hypomorphic Dnmt1 allele show genome-wide hypomethylation and develop
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T cell lymphomas with a high frequency of chromosome 15 trisomy (90). Induction of DNA
hypomethylation in Nf1+/- p53+/- mice also promotes tumor development by increasing the rate of loss of
heterozygosity, as a result of chromosomal instability due to hypomethylated centromeric and pericentric
regions (91). Finally, DNA hypomethylation results in loss of imprinting, which may also contribute to
tumorigenesis (92).
Recent correlation analysis between genomic and gene expression profiling in tumors samples
has shed some light into the molecular aspects of this dysregulation, and a few mechanisms have been
proposed to explain how DNA hypomethylation occurs in cancer cells. For instance, loss-of-function
mutations in DNMT3A are commonly found in hematological malignancies in adults and are implicated
in the development of leukemias (93). Experiments using mouse hematopoietic stem cells (HSCs)
revealed that Dnmt3a deletion results in increased self-renewal capacity instead of differentiation,
leading to the expansion of this population, suggesting a potential early mechanism for malignant
transformation. Moreover, Dnmt3a deficient HSCs show substantial global DNA hypomethylation (94).
Mice recipients of Dnmt3a-null HSCs develop multiple myeloid and lymphoid leukemias, recapitulating
human malignancies containing DNMT3A mutations (95-97). In contrast, Dnmt3a heterozygous HSCs
are prone to develop only myeloid leukemias (97), suggesting that DNMT3A behave as a
haploinsufficient tumor suppressor gene in myeloid leukemias (93). In clear agreement with this
hypothesis, 65% of the DNMT3A mutations found in acute myeloid leukemia (AML) are heterozygous
missense mutations altering the residue R882 at the C-terminal catalytic domain of the protein (93). It
has also been shown that the R882H mutation (R878H in mouse) has a dominant-negative effect on the
wild-type DNMT3A protein, as the mutant DNMT3A can dimerize with wild-type protein (38), but the
R882H mutation disrupts the formation of tetramers, which have significantly higher activity. Therefore,
in the absence of functional tetramers, mutant DNMT3A dimers with impaired catalytic activity lead to
global DNA hypomethylation observed in AML patients with R882 mutation (93, 97-99).
Furthermore, alterations of the maintenance methylation machinery have also been proposed to
drive the loss of DNA methylation in cancer. In fact, upregulation of UHRF1 expression has been
detected in different types of cancer and correlates with global DNA hypomethylation and tumorigenesis
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(100-105). As mentioned previously, UHRF1 has E3 ubiquitin ligase activity through its RING domain
and it has been shown to ubiquitinate DNMT1, DNMT3A and UHRF1 itself, leading to their degradation
and consequently DNA hypomethylation in cancer cells (104, 106-108). Moreover, genetic experiments
using zebrafish as a model demonstrate that overexpression of human UHRF1 in hepatocytes leads to
mislocalization of DNMT1 in the nucleus and to the reduction of its protein levels due to proteosomal
degradation, which results in global DNA hypomethylation and hepatocellular carcinoma (109).
Importantly, DNA hypomethylation by UHRF1 overexpression causes p53-dependent senescence, and
tumorigenesis only occurs after senescence is bypassed (109). In addition to the described mechanisms,
many molecular defects that lead to DNA hypomethylation likely alter the function of the DNMT1UHRF1 complex. For example, DNMT1 phosphorylation by AKT and/or PKC has been shown to
abrogate the formation of the DNMT1-UHRF1 complex in cancer cells (110). Importantly, global DNA
hypomethylation through disruption of the DNMT1-UHRF1 complex has also been reported to cause
transformation in non-tumorigenic cells and development of tumors in mice (110, 111).
Despite the progress, the mechanisms underlying DNA hypomethylation in cancer are largely
unclear. In Chapter 4, I identified a novel epigenetic mechanism that negatively regulates DNA
methylation by inhibiting the recruitment of the DNMT1-UHRF1 complex to chromatin, which is
dysregulated in cancer leading to global DNA hypomethylation.

1.5 CROSSTALK BETWEEN DNA METHYLATION AND ARGININE METHYLATION

The current knowledge about the activity and function of DNA methylation indicates that
DNMTs do not have an evident specificity for target DNA sequences rather than CpG dinucleotides,
which implies that the chromatin structure drives their correct targeting within the genome. Multiple
lines of evidence support the interaction between DNA methylation and different epigenetic
mechanisms. Indeed, the regulation of DNA methylation by histone modifications, particularly histone
lysine methylation, is well documented. For example, H3K9me3 generally correlates with DNA

20

methylation, whereas H3K4me3 inhibits DNA methylation. However, much less is known about the
crosstalk between DNA methylation and arginine methylation.

Arginine methylation
Modification of proteins by methylation of arginine residues is an important post-translational
modification (PTM) that is involved in several biological process, including transcription regulation,
DNA damage response, mRNA splicing and translation and modulation of different signaling pathways
(112, 113). Recent proteomic studies indicate that arginine methylation is as common as other more
studied PTMs, such as phosphorylation and ubiquitination, as it regulates the function of multiple
cytoplasmic and nuclear targets, including histone and non-histone substrates (114). The major role for
arginine methylation is the regulation of the binding by interacting proteins as, in contrast to other PTMs,
methylation does not change the charge of arginine residues and instead creates a docking site for
“readers”, such as tudor domain-containing proteins (115). Consistent with its importance in multiple
biological processes, dysregulation of arginine methylation is associated with multiple human diseases,
including cancer (112, 113).
Arginine methylation is carried out by the protein arginine methyltransferase (PRMT) family,
which consists of nine members that fall into three categories. Type I (PRMT1, PRMT2, PRMT3,
PRMT4, PRMT6, and PRMT8) and type II (PRMT5 and PRMT9) enzymes catalyze the formation of wNG-monomethylarginine (MMA) as

an

intermediate

before

generating

w-NG,NG-asymmetric

dimethylarginine (aDMA) and w-NG,N¢G-symmetric dimethylarginine (sDMA), respectively, whereas the
sole type III enzyme PRMT7 catalyzes only the formation of MMA (112, 116). Overexpression and
mutation of PRMTs are frequently observed in cancer (Table 1).
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Table 1: The human protein arginine methyltransferase family in cancer.
Enzyme
PRMT1

Other name

Modification

Cancer implication

References

ADMA

up to 5.5% overexpression (uterine, bladder, (113, 117-121)
pancreas, breast, lung); up to 2.8% mutated
(cervical, uterine, melanoma); other
alterations (MLL)
PRMT2
ADMA
up to 3.5% overexpression (ovarian,
(113, 117, 118)
bladder, AML, sarcoma, breast); up to 2.8%
mutated (colon, uterine, lung); up to 1.4%
deletion (stomach, colon)
PRMT3
ADMA
up to 3.8% mutated (uterine, lung, stomach, (113, 117, 118,
colon, melanoma); up to 2% overexpression 122)
(bladder, stomach, sarcoma); regulated by
DAL-1/4 tumor suppresor gene
PRMT4
CARM1
ADMA
up to 11.3% overexpression (uterin, ovarian, (113, 117, 118,
ACyC, ACC, sarcoma, glioma, colon,
120, 123-125)
breast, prostate, lung, liver); up to 2%
mutated (uterine, bladder, lung, head and
neck, melanoma)
PRMT5
SDMA
up to 4% mutated (uterine, head and neck,
(113, 117, 118,
bladder, colon, melanoma, leukemia,
126-128)
lymphoma); up to 3% overexpression
(ovarian, lung, sarcoma, glioma, breast,
liver, glioblastoma)
PRMT6
ADMA
up to 3.6% overexpression (prostate,
(113, 117, 118,
melanoma, sarcoma, bladder, lung); up to
121, 129)
1.6% mutated (lung, uterine, liver)
PRMT7
MMA
up to 6.6% deletion (prostate, ovarian,
(113, 117, 118,
breast, AML); up to 4% mutated (bladder,
130)
lung, uterine, stomach, melanoma, colon)
PRMT8
ADMA
up to 11% overexpression (ovarian, uterine, (117, 118)
bladder, glioma, sarcoma, head and neck,
breast, glioblastoma); up to 7% mutated
(lung, melanoma, colon)
PRMT9
SDMA
up to 3.8% mutated (uterine, stomach,
(117, 118)
colon, bladder, lung, esophageal, liver,
glioblastoma); up to 3.6% overexpression
(uterine, prostate, ovarian, sarcoma, breast,
lung)
MMA, monomethylarginine; ADMA, asymmetric dimethylarginine; SDMA, symmetric
dimethylarginine; AML, acute myeloid leukemia; ACyC, Adenoid Cystic Carcinoma; ACC,
Adrenocortical Carcinoma. Adapted from the original version (131).
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Regulation of DNA methylation by histone arginine methylation
A few studies explored the crosstalk between histone arginine methylation and DNA
methylation. Zhao and colleagues reported that the protein arginine methyltransferase 5 (PRMT5)
mediates histone H4R3 symmetric dimethylation (H4R3me2s), which serves as a binding site for
DNMT3A through its ADD domain (132). However, this mechanism remains to be confirmed, as other
studies reported evidence that does not support it (23, 133). Using biochemical approaches, Otani and
colleagues were unable to reproduce the binding between the ADD domain of DNMT3A and H4R3me2s
peptide (23). Likewise, another study using ChIP-seq analysis reported that, despite the fact that
H4R3me2s was found in CpG-rich promoters, downregulation of this modification with PRMT5
knockdown did not alter DNA methylation (133). Therefore, the role of PRMT5 in de novo DNA
methylation is still controversial.
A recent study identified the protein methyltransferase-like 23 (Mettl23) as a new arginine
methyltransferase that catalyzes asymmetric dimethylation of histone H3 at arginine 17 (H3R17me2a) in
maternal histone H3.3, and that this modification is required for the incorporation of H3.3 in the de novo
assembly of paternal nucleosomes in zygotes (134). Notably, this study further showed that H3R17me2a
and Mettl23 are required for the recruitment of TET3 to the male pronucleus, which results in the active
demethylation of the paternal genome to facilitate efficient reprograming (134).
Together, these studies suggest possible roles for histone arginine methylation in the regulation
of DNA methylation in mammals. Nevertheless, the functional and mechanistic links between arginine
methylation and DNA methylation remain largely unknown.

PRMT6 and its role in cancer
PRMT6 is the primary enzyme responsible for catalyzing methylation of histone H3 at arginine 2
(H3R2) to generate the aDMA form (H3R2me2a), which is an epigenetic modification associated with
transcriptional repression (68-70, 135). In fact, multiple studies have shown that PRMT6-dependent
H3R2me2a is mutually exclusive with H3K4me3, and that it inhibits the recruitment of the MLL
complex to the N-terminal tail of histone H3 (68-70, 135). Therefore, under normal conditions, PRMT6
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acts a transcriptional repressor by inhibiting H3K4me3 and the recruitment of coactivator complexes to
gene promoters.
Importantly, PRMT6 is frequently overexpressed in cancer cells and has been implicated in
different tumorigenic functions involving the methylation of histones and non-histones targets (113).
Among these, it has been shown that PRMT6 functions both as a transcription co-activator of oncogenic
pathways and as a repressor of tumor suppressor genes (113, 136). Studies using cancer cell lines have
reported that PRMT6 binds to the hormone receptors ER, AR, GR, and PR-B and facilitates their
transcriptional functions (137, 138). It also binds to PELP1, a proto-oncogene in breast cancer that
function as an ER co-activator (139). On the other hand, PRMT6 serve as a transcriptional repressor of
cyclin-dependent kinase (CDK) inhibitors p21 and p16 in osteosarcoma and breast cancer cells, thus
acting as an oncogene that promotes cell proliferation and prevents senescence (140-142). Moreover, p21
and p16 are also methylation substrates of PRMT6, which results in inhibition of their cell cycle
regulatory functions (143, 144). PRMT6 also represses transcription of the tumor suppressor gene Trp53,
and PRMT6 overexpression results in lower levels of p53 (145). In addition to regulating transcription,
PRMT6 oncogenic functions also involve the regulation of alternative splicing (136, 138, 139).
The evidence described above indicates that PRMT6 has important roles in cancer development
and progression. However, it is not clear whether PRMT6 activity is involved in the early steps of
malignant transformation, or it is required for tumor progression. Moreover, the significance of the
transcriptional functions of PRMT6 in tumorigenesis remains to be determined. In Chapter 4 of this
dissertation, I discovered a new role for PRMT6 as a negative regulator of maintenance DNA
methylation and showed that upregulation of PRMT6 contributes to global loss of DNA methylation in
cancer cells.
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CHAPTER 2: Materials and Methods

Part of this chapter is based upon: Veland, N., Hardikar, S., Zhong, Y., Gayatri, S., Dan, J., Strahl, B.D.,
Rothbart, S.B., Bedford, M.T. and Chen, T. (2017) The Arginine Methyltransferase PRMT6 Regulates
DNA Methylation and Contributes to Global DNA Hypomethylation in Cancer. Cell Rep, 21, 33903397.

Used with permission of Elsevier.
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Mice: The Dnmt3L null allele, generated by Hata et al. (42), was maintained on the 129
background. Zygotic Dnmt3L knock-out (Dnmt3L zKO) and Dnmt3L wild-type zygotes and blastocysts
were obtained from inter-crosses between heterozygous (Dnmt3L+/-) mice, whereas maternal Dnmt3L
KO (Dnmt3L mKO) and double maternal and zygotic knock-out (Dnmt3L mzKO) zygotes and
blastocysts were obtained from crosses between homozygous (Dnmt3L-/-) females and Dnmt3L+/- males.
Dnmt12lox/+ knock-in chimera mice were backcrossed into C57BL/6J strain background. Then,
this mice were crossed with Zp3-Cre transgenic mice to activate the 3XFlag-Dnmt1 knock-in allele, and
their female progeny was crossed with wild-type C57BL/6J mice to generate Dnmt1Flag/+ mice.
Heterozygous intercrossed provide homozygous (Dnmt1Flag/Flag) knock-in mice.
All procedures were performed according with the National Institutes of Health Guide for the
Care and Use of Laboratory animals, with Institutional Care and Use Committee-approved protocols at
The University of Texas MD Anderson Cancer Center (MDACC).

Isolation of zygotes and derivation of mouse embryonic stem cells from blastocysts: For
isolation of zygotes and blastocysts, Dnmt3L heterozygous or homozygous null mice were superovulated
and mated with wild-type males. Zygotes were collected from the oviducts at E0.5 and released into a
hyaluronidase/M2 medium (Millipore) for dissociation. Derivation of mouse embryonic stem cells
(mESCs) was performed essentially as previously described (146). Briefly, mice were euthanized at E3.5
and blastocysts were flushed out of the uterus using M2 medium (Sigma). Then, blastocysts were placed
on a feeder cell layer of irradiated mouse embryonic fibroblasts in Serum-free ES medium with 2i, which
consist of a 1:1 mixture of Dulbecco modified Eagle medium-F12/N-2 (DMEM-F12 supplemented with
N-2, Invitrogen) and Neurobasal/B27 (Neurobasal supplemented with B27, Invitrogen) with 0.5%
(vol/vol) penicillin- streptomycin (Invitrogen), 1 mM GlutaMAX (Invitrogen), 0.5 mM sodium pyruvate
(Invitrogen), 0.1 mM non-essential amino acids (Invitrogen), 0.1 mM 2-mercaptoethanol (Sigma), 103 IU
of LIF (Millipore), 1 µM PD0325901 and 3 µM CHIR99021 (S1036 and S2924, respectively,
Selleckchem). After blastocyst hatching, the inner cell mass clumps were picked under the microscope
and plated into 96-well plate with feeder cells. The newly established mESCs lines were expanded,
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adapted to DMEM FBS mESC medium [DMEM supplemented with 15% fetal bovine serum
(Invitrogen), 0.5% (vol/vol) penicillin- streptomycin (Invitrogen), 0.1 mM non-essential amino acids
(Invitrogen), 0.1 mM 2-mercaptoethanol (Sigma), 103 IU of LIF (Millipore)] and then either frozen or
used for further analysis. The cells were then normally grown on gelatin-coated petri dishes without
feeder cells.

Cell culture and manipulations: For the generation of stable mESCs clones expressing MycDnmt3L, Myc-Dnmt3L F297D, Myc-Dnmt3a1, Myc-Dnmt3a2, Myc-PRMT6 or Myc-PRMT6 E155Q,
cells transfected with the corresponding plasmids were seeded at low density on dishes coated with
feeder cells, selected with 6 µg/mL of Blasticidin S HCl (Gibco) for 7-10 days, and colonies were
picked. Transfection was performed using Lipofectamine 2000 (Invitrogen). Experiments where cells
were treated with cycloheximide (C4859, Sigma) were carried out at 100 µg/mL. MG-132 (M7449,
Sigma) was used at 10 µM, while Bafilomycin A1 (B1793, Sigma) at 125nM. For all treatments, DMSO
was used as control. Human cancer cell lines were cultured according to instructions of American Type
Culture Collection. For PRMT6 knockdown, MCF7 cells transfected with shRNA plasmids were
selected and maintained in medium containing 1 µg/ml of puromycin (Gibco). To inhibit PRMT6
activity, cells were treated with 10 µM of MS023 (147)

Antibodies: For Western blots: anti-Myc (Sigma M4439; 1:5,000), anti-Flag (Sigma F3165;
1:5,000), anti-DNMT1 (Cell Signaling 5032; 1:1,000), anti-DNMT1 N-terminal (Novus Biologicals 100264; 1:1,000), anti-Dnmt3a (Abcam 13888; 1:2,000), anti-Dnmt3b (Abcam 13604; 1:2,000), antiDnmt3L (Cell Signaling 12309; 1:1,1000), anti-p53 (Cell Signaling 2524; 1:1,1000), anti-LC3B (Cell
Signaling 2775; 1:1,1000), anti-UHRF1 (Cell Signaling 12387; 1:1,000), anti-PRMT6 (Bethyl A300929A; 1:2,000), anti-PCNA (Cell Signaling 2586; 1:8,000), anti-Usp7 (Cell Signaling 4833; 1:1,000),
anti-HP1a (Thermo Fisher PA5-17441; 1:2,000), anti-a-tubulin (Cell Signaling 2144; 1:2,000), anti-bactin (Sigma A5441; 1:5,000), anti-H3R2me2a (Millipore 05-808; 1:2,000), anti-H3K4me3 (Active
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Motif 39159; 1:2,000), anti-H3K9me3 (Millipore 07-442; 1:2,000), anti-H3 (Cell Signaling 9715;
1:8,000), anti-Oct4 (Abcam 19857; 1: 1,000), anti-Sox2 (Abcam 97959; 1: 1,000), anti-Nanog (Abcam
80892; 1: 1,000), and anti-pan asymmetric dimethyl arginine (Rme2a) (Cell Signaling 13522; 1:2,000).
For immunofluorescence (IF): anti-Oct4 (Abcam 19857; 1:300), anti-Sox2 (Abcam 97959; 1:300), and
anti-Nanog (Abcam 80892; 1:300). For chromatin immunoprecipitation (ChIP): anti-UHRF1 (Diagenode
C15410258), anti-H3R2me2a (Abcam 175007), and anti-H3 (Abcam 1791). For DNA methylation: anti5mC (Millipore MABE146; 1:1,000 for dot blot, 1:2,000 for IF, 2 µg for MeDIP), anti-5hmC (Active
Motif 39769; dilution for 1:1,000 for IF).

Plasmid constructs: The vectors containing Myc-tagged Dnmt3L, Dnmt3a1 and Dnmt3a2 were
generated by PCR amplification of the corresponding mouse cDNA from mESCs, using the primers
indicated in Table 2. Amplified PCR products were cloned into the pCAG-IRESblast vector (32). The
pCAG-Myc-PRMT6-IRESblast vector was generated by sub-cloning Myc-tagged human PRMT6 cDNA
into the pCAG-IRESblast vector. The Dnmt3L F297D and PRMT6 E155Q point mutations were
introduced by PCR-based mutagenesis (see Table 2 for primer sequences). The pGIPZ (tGFP-IRESPuro) control and PRMT6 shRNA plasmids were obtained from GE Healthcare Dharmacon. Untagged
Dnmt1 with alternative translation start site were cloned into the of pCAG-HA-IRESblast (148), using
SpeI and NotI to remove the HA tag.

Southern blot analysis: DNA methylation levels at major satellite repeats, minor satellite repeats
and intracisternal A-particle (IAP) retrotransposons were analyzed by Southern blot after digestion of 2
µg of genomic DNA with the methylation-sensitive restriction enzymes MaeII (Roche) or HpaII (New
England Biolabs) as previously reported (32). Briefly, digested DNA was separated by agarose gel
electrophoresis and then transferred onto nylon membranes. For hybridization, the membranes were
incubated with biotin-labeled probes (500 ng for major and minor satellites and 2.5 µg for IAP)
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overnight at 42°C. Signal detection was performed using North2South Chemiluminescent Hybridization
and Detection Kit (Thermo Scientific). See Table 2 probes sequences.

Bisulfite sequencing: For bisulfite sequencing, genomic DNA was treated for bisulfite
conversion using the EZ DNA Methylation kit (Zymo) and then used as template to amplify the 45S
rDNA promoter with Taq DNA polymerase (Qiagen) using primers described in the Table 2. PCR
conditions consisted of 40 cycles of denaturation at 94°C for 30 sec, annealing for 30 sec at 60°C and
extension at 72°C for 30 sec. Following a final extension at 72°C for 5 min, PCR products were gel
purified and directly ligated into pMiniT 2.0 using the NEB PCR cloning kit (New England Biolabs)
according to the manufacturer's protocol. Qiagen Miniprep DNA was sequenced and results were
analyzed with QUMA web-based quantification tool for methylation analysis (http://quma.cdb.riken.jp)
(149). Percentages of methylated CpG sites were calculated from individual clones.

RNA isolation and RT-qPCR: Total RNA was from ESCs using the Tryzol (Invitrogen)
according to the manufacturer's instruction, followed by reverse transcription (RT) using ProtoScript
First Strand cDNA Synthesis kit (New England Biolabs) to generate cDNA. Relative quantification of
mRNA levels was carried out by RT-qPCR using iTaq Universal SYBR Green Supermix (Bio-Rad) in
the ABI 7900 Real-Time PCR system (Applied Biosystems) using primers provided in Table 2.

Chromatin immunoprecipitation (ChIP): ChIP experiments were performed according to the
Abcam X-ChIP protocol with modifications. Briefly, a total of 1 x 107 of mESC or MCF7 cells were
cross-linked with 1% formaldehyde for 10 min at room temperature. Fixation reaction was quenched
with 125 mM glycine for 5 min. Cells were washed twice with 1X PBS, lysed in SDS buffer [50 mM
Tris-HCl (pH 8.1), 10 mM EDTA, 1% SDS and 1X protease inhibitor cocktail (Thermo Scientific)] and
sonicated for 50 cycles (30 sec ON, 30 sec OFF) using Bioruptor Plus (Diagenode) to obtain chromatin
fragments of 300-500 bp. Sonicated chromatin was centrifuged at 14.5 K rpms for 10 min at 4°C, and
the supernatant was 5-fold diluted with dilution buffer [16.7 mM Tris-HCl (pH 8.1), 167 mM NaCl, 1.2
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mM EDTA, 1% Triton X-100, 0.1% SDS and 1X protease inhibitor cocktail (Thermo Scientific)]. Each
sample was pre-cleared with 30 µl of Dynabeads M-280 sheep anti-rabbit IgG (Thermo Scientific) for 2
hours at 4°C, followed by incubation with specific antibodies overnight at 4°C. Samples were incubated
with Dynabeads M-280 sheep anti-rabbit IgG for 1 hour at 4°C, followed by high stringency washes.
Beads were eluted twice at room temperature in elution buffer (100 mM NaHCO3, 1% SDS), and reverse
cross-linking was performed overnight at 65°C with 200 mM NaCl. Samples were then incubated with
RNase A at 37°C for 30 min followed by incubation with proteinase K at 55°C for 2 hours, and DNA
was purified using the QIAquick PCR Purification kit (Qiagen). Enrichment at selected loci was detected
by qPCR (see Table 2 for primer sequences) using iTaq Universal SYBR Green Supermix (Bio-Rad). Ct
values were normalized against 1% input.

Methylated-DNA immunoprecipitation (MeDIP): MeDIP was performed as described
previously (150). RNA-free genomic DNA was sonicated for 12 cycles (30 sec ON, 30 sec OFF) using
Bioruptor Plus (Diagenode) to obtain DNA fragments of 300-1000 bp. After sonication, a portion of
DNA was separated as input control. Each DNA sample was incubated with 2 µg of anti-5mC mouse
antibody (Millipore) in MeDIP buffer [10 mM Na-Phosphate (pH 7.0), 140 mM NaCl, and 0.05% Triton
X-100] for 3 hours at 4°C. Then, the samples were incubated with 30 µl of Dynabeads M-280 sheep antimouse IgG (Thermo Scientific) for 1 hour at 4°C, followed by three washes with MeDIP buffer. Beads
were incubated with proteinase K overnight at 55°C in constant agitation, and DNA from MeDIP and
input were purified using the QIAquick PCR Purification kit (Qiagen). Methylated DNA enrichment at
selected loci was detected by qPCR (see Table 2 for primer sequences) using iTaq Universal SYBR
Green Supermix (Bio-Rad). MeDIP Ct values were normalized against 1% input.
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Table 2: Primers and Oligonucleotides used in this dissertation.
Assay

Target

Sequence (5’ to 3’)

Reference

Cloning
Cloning
Cloning
Cloning

mDnmt3L (F)
mDnmt3L (R)
mDnmt3L F297D (F)*
mDnmt3L F297D (R)*

This study
This study
This study
This study

Cloning
Cloning
Cloning
Cloning

mDnmt3a1 (F)
mDnmt3a2 (F)
mDnmt3a (R)
mDnmt1 ∆1-607 (F)

Cloning

mDnmt1 ∆1-650 (F)

Cloning

mDnmt1 ∆1-675 (F)

Cloning

mDnmt1 ∆1-714 (F)

Cloning

mDnmt1 (R)

Cloning
Cloning
Cloning
Cloning
Southern
Blot

hPRMT6 (F)
hPRMT6 E155Q (R)^
hPRMT6 E155Q (F)^
hPRMT6 (R)
Major satellite repeat
probe

Southern
Blot

Minor satellite repeat
probe

AGGGAATTCCCGGGAGACACCTTCTTC
TCAGAATTCTAAAGAGGAAGTGAGTTTTG
CTGGTACATGgaCCAGTTCCACCGGATCCT
GTGGAACTGGtcCATGTACCAGCCGGGAC
A
CCTGAATTCGCCCTCCAGCGGCCCCGG
TGCGAATTCGAATGCTGTGGAAGAGAAC
CACGAATTCAGTTTGCCCCCATGTCCCT
CAAACTAGTCCACCATGGGTGCTACCAA
GGAGAAG
ACAACTAGTCCACCATGAAGCGCCGCCG
CTGTG
AGGACTAGTCCACCATGGTGAAGTTTGGT
GGCAC
ATGACTAGTCCACCATGCCATCACCCAAA
AAGCTG
CATGCGGCCGCTAGTCCTTGGTAGCAGCC
TCCTC
GTAGAATTCGTCGCAGCCCAAGAAAAG
CCCATCCACTgGCTCACGATGGCATCCAC
CATCGTGAGCcAGTGGATGGGCTACGGAC
GCTGAATTCAGTCCTCCATGGCAAAGTC
TTAGAAATGTCCACTGTAGGACGTGGAAT
ATGGCAAG
ACTGAAAAACACATTCGTTGGAAACGGG
ATTTGTAGAACAGTGTATATCAATGAGTT
ACAATGAG
GATGTAAGAATAAAGCTTTGCCGCAGAA
GATTCTGGTCTG
GTTCTACCGCCTCCTGCATGATGC
GCCCTGTGTGCAGCAGACACTTC
GAGGCCTGGCCGGAAGCGCAAGCAC
GTCTCAGTTCCCTCTCCTTCAGCTG
GAGGGGCTGCACCTGGCCTTATG
AGCATCCCCTCCTACTGGCTCAG
GGAGGCCCATTAGAGTCCTGTCTC
CACCAATCACCAAGTCGAACGGGC
AAGAGAGGCCCTATCCCAACTC
TTGTGGGTGCAGCGAACTTTATTG
TGGGCGGCCGCCATGGCAGACTCAAATA
GATC
GACGGATCCTAGTTCCCCTCTTCCGACTC
TTC
GAGAACCACCAGGCAGAC
GTTCACATGGCTCTTCCGGACCCAG
CTGTTCCTGGTGGGCGAGTGC
GTAAGTCTTGCCATCCTCAG
CATGGTGCTGAAGCTCACACTGCG
CAGCCAAGATGATGGCCCTCCTTC

Southern
Blot
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR

IAP probe
mDnmt3a (F)
mDnmt3a (R)
mDnmt3a1 (F)
mDnmt3a1 (R)
mDnmt3a2 (F)
mDnmt3a2 (R)
mDnmt3b (F)
mDnmt3b (R)
mGAPDH (F)
mGAPDH (R)
mDnmt1 exon 4 (F)
mDnmt1 exon 6 (R)
mDnmt1 exon 5 (F)
mDnmt1 exon 8 (R)
mDnmt1 exon 25 (F)
mDnmt1 exon 26 (R)
mDnmt1 exon 33 (F)
mDnmt1 exon 34 (R)

This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
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ChIP-PCR
ChIP-PCR

IAP (F)
IAP (R)

ChIP-PCR

MSR (F)

ChIP-PCR

MSR (R)

Bisulfite
sequencing
Bisulfite
sequencing
ChIP-PCR
& MeDIPPCR
ChIP-PCR
& MeDIPPCR
ChIP-PCR
& MeDIPPCR
ChIP-PCR
& MeDIPPCR
ChIP-PCR
& MeDIPPCR
ChIP-PCR
& MeDIPPCR

Human 45S rDNA
promoter (F)
Human 45S rDNA
promoter (R)
Human HOXA2
promoter (F)

CAAATAATCTGCGCATATGCCGA
GACCAGAATCTTCTGCGGCAA
TGATATACACTGTTCTACAAATCCCGTTT
C
ATCAATGAGTTACAATGAGAAACATGGA
AA

(151)
(151)
(152)

GTGTGTTTTGGGGTTGATTAGAG

This study

TCCGAAAACCCAACCTCTCCAAC

This study

(152)

(69)
CGGTCCCCATACGGCTGTA

Human HOXA2
promoter (R)

CAGGCTGGGAATGGTCTGCT

(69)

Human CDKN1A
promoter (F)

TGCGTTCACAGGTGTTTCTG

Human CDKN1A
promoter (R)

CACATCCCGACTCTCGTCAC

Human GREB1C
promoter (F)

TTGTTGTAGCTCTGGGAGCA

Human GREB1C
promoter (R)

CAACCAGCCAAGAGGCTAAG

(142)
(142)
(139)
(139)

F, forward; R, reverse. Continuous underlined sequences indicate EcoRI site, spaced underlined
sequences indicate SpeI site and double underlined sequence indicate NotI site

used for cloning.

*Primers used together with mDnmt3L (F) and mDnmt3L (R) to generate mDnmt3L F297D mutation
(altered nucleotide in lower case). ^Primers used together with hPRMT6 (F) and hPRMT6 (R) to
generate hPRMT6 E155Q mutation (altered nucleotide in lower case).

32

Immunofluorescence (IF) analysis: Zygotes were fixed in 3.7% paraformaldehyde in PBS for
30 min at room temperature and permeabilized for 15 min in 0.1% Triton X-100 in PBS at room
temperature. For 5mC and 5hmC staining, conditions were essentially as previously described (153).
Images were taken with Olympus IX51 inverted fluorescence microscope at 60X magnification. For
mESCs IF, cells were cultured on gelatin-coated glass coverslips, fixed with 3.7% paraformaldehyde and
then permeabilized with 0.1% Triton X-100. After blocking with 1% bovine serum albumin and 10%
donkey serum (Sigma), cells were incubated with primary antibodies at 4 °C overnight. Finally, cells
were labeled with Alexa Fluor conjugated secondary antibodies and nuclear stained with DAPI. For 5mC
IF, the cells were incubated with 2N HCl at room temperature for 40 min and then neutralized with 0.1
M sodium borate (pH 9.0) for 15 min before the blocking step. Images were taken with Olympus IX51
inverted fluorescence microscope at 40X magnification.

Isolation of small intestinal crypts: The duodenum section of small intestine from 6-8 weeks old
mice was removed and flushed with 1X PBS. Intestinal crypts were isolated essentially as previously
described (154). Briefly, intestine pieces were incubated in constant agitation at 4°C with cold crypt
chelating buffer (2 mM EDTA in 1X DPBS) and then epithelium was disassociated from basement
membrane by gently agitation in cold dissociation buffer (54.9 mM D-sorbitol, 43.4 mM sucrose in 1X
DPBS). Cell suspension was then filtered with 70 µm cell strainer to remove villi. Crypts were purified
by centrifugation 150 g for 10 min in dissociation buffer and purity was verified under microscope.
Sufficient amount of intestinal crypts was obtained from one mouse preparation to be divided in three
separate tubes to extract protein, DNA and RNA.

Immunohistochemistry on tissue sections: Duodenum was initially processed as describe above
for crypt isolation. Duodenum pieces were formalin fixed and embedded in paraffin and longitudinal 4
µm sections were prepared. After dewaxing and re-hydration, antigen retrieval was achieved in citrate
buffer pH 6.0 at 96°C for 20 min. Immunohistochemistry was performed using standard procedures.
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Western blot and immunoprecipitation: For regular analysis of whole cell extracts by western
blots, mESCs were lysed in cold RIPA buffer [50 mM Tris-HCl (pH 8.8), 150 mM NaCl, 1% Triton X100, 0.5% Sodium Deoxycholate, 0.1% SDS, 1 mM EDTA, 3 mM MgCl2, and 1X protease inhibitor
cocktail (Thermo Scientific 1861279)]. Immunoprecipitation was performed in lysis buffer [20mM TrisHCl (pH 7.9), 150 mM NaCl, 0.1% NP-40, 1 mM EDTA, 3 mM MgCl2, 10% Glycerol, 1X protease
inhibitor cocktail (Thermo Scientific 1861279)] using Protein A/G UltraLink Resin beads (Thermo
Fisher 53133). Western blots were performed according to standard procedures. Quantification of
westerns blots by densitometry was carried out using NIH Image J software (155).

Mass spectrometry proteomic analysis: After Flag immunoprecipitation using M2 beads
(Sigma), protein samples were eluted from beads using 3X Flag peptide (Sigma) under constant agitation
for 1 hour at 4°C, and sample volume was concentrated by centrifugation using columns. Then, samples
were separated by PAGE, gels were Coomasie stained and protein bands were excised from the gel.
After in-gel trypsin digestion, samples were run on the Dionex LC and Orbitrap Fusion for LC-MS/MS
with a 30 minute run time. Peptide mapping analysis was performed using Scaffold version 4.8
(Proteome Software).

Dot blot analyses: RNA-free genomic DNA was denatured in 0.4 N NaOH, 10 mM EDTA at
95°C for 10 min before spotting various amounts (0.25-1 µg) on nylon membranes using a Bio-Dot
apparatus (Bio-Rad). The membranes were then incubated with anti-5mC antibody (1:1,000) overnight at
4°C. Enhanced chemiluminescence signal detection was carried out in the ImageQuant LAS 4000
imaging system (GE Healthcare Life Sciences) with a CCD camera using chemiluminescence filter and
automatic exposure settings. To verify equal loading of different DNA samples, membranes were stained
with SYTOX Green nuclei acid stain (Invitrogen S7020; 1:10,000) for 10 minutes at room temperature.
Fluorescent green signal was detected using the Cy2 filter and automatic exposure settings. Dot blot
quantification was carried out by densitometry using the NIH Image J software (155).
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Reduced Representation Bisulfite Sequencing (RRBS) and Bioinformatics Analyses:
Experiment: RRBS libraries were made from 1 µg of genomic DNA, according to published protocols
(156, 157). In brief, the genomic DNA was digested with MspI, end-repaired and A-tailed, and Illuminacompatible cytosine-methylated adaptors (Bio Scientific) were ligated to the enzyme-digested DNA.
Size-selected fragments representing sequences from 40 to 170 bp were bisulfite-converted using the EZ
DNA Methylation-Gold Kit (Zymo Research) and library preparation was done by PCR amplification.
The libraries were sequenced using 36 bases single-read protocol on Illumina HiSeq 2000 instrument.
Three biological replicates were prepared for each condition (one Dnmt3L KO sample was discarded in
the later analysis due to the quality problem). 12-35 million reads were generated per sample. Mapping:
The adapters were removed from the 3’ ends of the reads by Trim Galore! version 0.4.1
(https://www.bioinformatics. babraham.ac.uk/projects/trim_galore/) and cutadapt version 1.9.1 (158).
Then, the reads were mapped to mouse genome mm10 by the bisulfite converted read mapper Bismark
version 0.16.1 (159) and Bowtie version 1.1.2 (160). 95-96% reads were mapped to the mouse genome,
with 65-68% uniquely mapped. 8-23 million uniquely mapped reads were used in the final analysis.
Methylation Calling: The methylation percentages for the CpG sites were calculated by the
bismark_methylation_extractor script from Bismark and an in-house Perl script. Differential
Methylation: the differential methylation between conditions was statistically assessed by
R/Bioconductor package methylKit version 0.9.5 (161) at site resolution and 500 bp tile resolution. Only
the CpG sites with read coverage ≥ 20 or the tiles that have at least three CpG sites with coverage ≥ 10 in
all the samples were qualified for the test. The CpG sites or 500 bp tiles with qvalue ≤ 0.01 and
methylation difference ≥ 25% were called as differentially methylated. Gene Annotation: each site or
tile was assigned to a location relative to the nearby genes: upstream (-5k to -1k from TSS), promoter (1k to +0.5k from TSS), exon, intron, TES (-0.5k to +1k from TES), downstream (+1k to +5k from TES)
and intergenic. In the case a site/tile could be assigned to multiple locations relative to different genes,
one location was chosen following this order: promoter > upstream > TES > downstream > exon > intron
> intergenic. The genes are the RefSeq genes (162) downloaded from UCSC genome browser
(http://genome.ucsc.edu/) on July 17, 2015.
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MeDIP-seq: The raw reads and the peaks called for shGFP and shDnmt3L were obtained from
Neri et al. (49), data accessible at NCBI Gene Expression Omnibus (GEO) database, accession
GSE44642. The reads were mapped to mouse genome mm9 by Bowtie version 1.1.2 (160), with at most
1 mismatch allowed, and only the reads that were mapped to unique position were retained. To avoid
PCR bias, for multiple reads that were mapped to the same genomic position, only one copy was retained
for further analysis. The overlapping or book-ended peaks of shGFP and shDnmt3L were merged, and
the number of reads in each of the merged peaks was counted for shGFP and shDnmt3L separately. The
differential methylation between shGFP and shDnmt3L was statistically assessed by binomial test on
each merged peak, with the hypothesized probability of success determined by the total number of reads
mapped to the two samples or the number of reads mapped to all the merged peaks in the two samples.
The pvalues were corrected to false discovery rate (FDR) by Benjamini & Hochberg (BH) method. The
peaks with FDR≤ 0.05 and fold change ≥ 2 were called as differentially methylated between shGFP and
shDnmt3L.

Histone acid extraction: Cells were lysed in cold mild lysis buffer containing 10 mM Tris-HCl
(pH 7.5), 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 1X protease inhibitor cocktail (Thermo
Scientific 1861279), and 1X phosphatase inhibitor cocktail (Thermo Scientific 78427). Lysates were then
sonicated in Bioruptor Plus (Diagenode) for 10 cycles (5 sec ON, 30 sec OFF), centrifuged at 14,500 rpm
in 4°C for 15 minutes, and final pellets were washed once in mild lysis buffer. To extract histones,
pellets were resuspended in 0.8 N HCl, sonicated for 20 cycles (15 sec ON, 30 sec OFF) and incubated at
4°C for 1 hour in constant agitation. Soluble histones were clarified by centrifugation at 13,000 rpm in
4°C for 10 min and neutralized with 2 M Tris-HCl (pH 8.0).

Nuclear fractionation: Nuclear fractionation in mESCs was carried out as described previously
(163) with the following modification: buffer B was replaced by buffer N [15 mM Tris-HCl (pH 7.5),
200 mM NaCl, 60 mM KCl, 5 mM MgCl2, 1 mM CaCl2, 0.3% NP-40, and 1X protease inhibitor cocktail
(Thermo Scientific)]. For experiments in MCF7, NaCl in buffer N was adjusted to 100 mM.
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Quantification of nuclear fractionation data: Areas from Western blots were measured by
densitometry using the NIH Image J software (155). UHRF1 areas were normalized against PCNA or
HP1a areas for soluble or chromatin fractions, respectively. UHRF1 percentages of soluble and
chromatin fractions from three independent nuclear fractionation experiments were plotted using
GraphPad Prism 6.

In vitro arginine methylation assay: In vitro arginine methylation reactions were performed in
30 µl of 1X PBS (pH 7.4) using beads bound to immunoprecipitated Myc-PRMT6 (wild type or E155Q
mutant) expressed in mESC stable clones as enzyme source, with 1 µg of recombinant histone H3 (New
England Biolabs) as substrate and 0.42 µM S-adenosyl-l-[methyl-3H] methionine (Perkin Elmer) as
methyl donor. Reactions were incubated at 30°C for 1 hour, resolved on SDS-PAGE, transferred to
PVDF membrane, treated with En3Hance (Perkin Elmer) and exposed to film at －80°C for 4 days.

Quantification of 5mC content by liquid chromatography-tandem mass spectrometry (LCMS/MS): Quantification of the total levels of 5mC in cancer cells was performed by LC-MS/MS
essentially as previously described (63). Briefly, 1 µg of RNA-free genomic DNA was denatured at 95°C
for 5 min and then cooled on ice, followed by addition of 0.1 vol of 0.1 M ammonium acetate (pH 5.3)
and incubation with 2 units of nuclease P1 (Sigma) for 2 hours at 45°C. Then, 0.1 vol of 1 M ammonium
bicarbonate and 0.002 units of phosphodiesterase I (Sigma) were added to the mixture and it was further
incubated for 2 hours at 37°C. Finally, 0.5 units of alkaline phosphatase (Sigma) were added and then
incubated for 1 additional hour at 37°C. At this point, the solution was ready for immediately analysis by
LC-MS/MS. The total deoxycytosine (dC) and 5-methyl-deoxycytosine (5mdC) levels were quantified
with an Agilent 1100 liquid chromatograph coupled to a Waters Quattro Premier mass spectrometer. The
5mC total level is expressed as a percentage of the total cytosine pool according to peak areas.
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TCGA Bioinformatic and statistical analysis: PRMT6 expression data and DNA methylation
data for breast cancer, lung adenocarcinoma and colorectal adenocarcinoma samples in The Cancer
Genome Atlas (TCGA) database were analyzed. The mean DNA methylation levels of samples with the
highest (top 20%) and lowest (bottom 20%) PRMT6 expression were compared either without taking
UHRF1 expression into consideration or by first dividing the samples into UHRF1-high (upper 70%) and
UHRF1-low (lower 30%) groups. Wilcoxon rank sum non-parametric test with two-tailed P values was
used to determine the significance of differences. Paired t test with a two-tailed p value was used for dot
blot data analysis and quantification graphs were generated using GraphPad Prism 6.
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CHAPTER 3: Regulation of de novo DNA methylation by DNMT3L in mESCs

39

3.1 INTRODUCTION

DNA methylation – the addition of a methyl group to the C-5 position of cytosine, forming 5methylcytosine (5mC) – occurs predominantly in the context of CpG dinucleotides. DNA methylation is
essential for mammalian development and plays crucial roles in various biological processes, including
regulation of gene expression, maintenance of genomic stability, genomic imprinting, and X
chromosome inactivation (3, 164). Aberrant DNA methylation patterns and genetic alterations of the
DNA methylation machinery are associated with numerous human diseases, including developmental
disorders and cancer (37, 165).
DNA methylation is catalyzed by two families of DNA methyltransferases (Dnmts). Dnmt1 is
the major enzyme responsible for maintenance methylation by “copying” the CpG methylation pattern
from the parental strand onto the daughter strand during DNA replication. Dnmt3a and Dnmt3b function
primarily as de novo methyltransferases for the establishment of DNA methylation patterns (3). Dnmt3c,
a Dnmt3b duplicated gene present exclusively in rodents, had been previously annotated as a pseudogene
(formerly known as Gm14490) but was recently shown to be expressed and play a specific role of de
novo methylation at retrotransposons during spermatogenesis (9). The Dnmt1 and Dnmt3 enzymes share
characteristic catalytic motifs in their C-terminal catalytic domains but have different N-terminal
regulatory regions that largely confer functional specificities of these enzymes. For example, Dnmt3a
and Dnmt3b contain two chromatin-binding domains in their N-terminal regions that likely play
important roles in targeting these enzymes to specific genomic regions – the PWWP domain, which is
required for heterochromatin targeting and mediates binding to trimethylated lysine 36 of histone H3
(H3K36me3) marks, and the ADD domain, which interacts with the N-terminal tail of histone H3 with
unmethylated lysine 4 (H3K4me0) (20, 21, 23).
Dnmt3L (Dnmt3-like), another member of the Dnmt3 family, shows sequence homology with
the Dnmt3 enzymes but lacks the very N terminus, including the PWWP domain, and some essential
catalytic motifs in the C-terminal region, including the PC dipeptide at the active site and the sequence
motif involved in binding of the methyl donor S-adenosyl-L-methioinine. Therefore, Dnmt3L has no
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enzymatic activity (42, 166). However, Dnmt3L has been shown to interact with Dnmt3a and Dnmt3b
and significantly stimulates their catalytic activities in vitro (166-168). Crystallography evidence reveals
that the C-terminal domain of Dnmt3L directly interacts with the C-terminal domain of Dnmt3a to form
a heterodimer, which further dimerizes through Dnmt3a-Dnmt3a interaction, resulting in the formation
of a tetramer with two Dnmt3a active sites at the center (43, 169, 170). Biochemical and structural data
also indicate that Dnmt3L, via its ADD domain, specifically recognizes H3K4me0 and may contribute to
the specificity of de novo DNA methylation (22). Additionally, the expression pattern of Dnmt3L during
development strongly correlates with active de novo methylation, with high expression in developing
germ cells and early embryos, as well as embryonic stem cells (ESCs), and little to no expression in most
somatic tissues. These findings suggest that Dnmt3L is a key regulator of de novo DNA methylation.
Genetic evidence supports the role of Dnmt3L as a regulator of de novo methylation. Dnmt3L
knock-out (KO) mice are viable and grossly normal, indicating that zygotic Dnmt3L is not essential for
embryonic development (42, 44). However, both male and female Dnmt3L KO mice cannot reproduce.
Male Dnmt3L KO mice show activation of retrotransposons in spermatogonia and spermatocytes, due to
failure in de novo methylation, resulting in severe spermatogenesis defects (42, 45). Female Dnmt3L KO
mice also fail to establish DNA methylation, including maternal genomic imprints, in oocytes. They are
able to conceive but show maternal-effect lethality – embryos die around mid-gestation – largely due to
abnormal expression of imprinted genes (42, 44). The phenotype of Dnmt3L KO mice is almost identical
to that of mice with conditional Dnmt3a deletion in germ cells (35), but different from the embryonic
lethal phenotype of Dnmt3b KO mice (29).
Although it is generally assumed that Dnmt3L acts as a catalytic cofactor of Dnmt3a and
Dnmt3b, the mechanism by which Dnmt3L regulates DNA methylation is not well understood. Also,
given that Dnmt3L is capable of interacting with and enhancing the activities of both Dnmt3a and
Dnmt3b, it has been puzzling that Dnmt3L is essential for Dnmt3a-mediated de novo methylation during
gametogenesis but is dispensable for Dnmt3b-mediated de novo methylation during embryogenesis.
Moreover, contrary to biochemical and genetic evidence that Dnmt3L functions as a positive regulator of
DNA methylation, Neri et al. recently showed that Dnmt3L antagonizes DNA methylation in many
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promoter regions and favors DNA methylation at gene bodies in mouse ESCs (mESCs) (49). To gain
further insights into the role and specificity of Dnmt3L in DNA methylation, we derived mESC lines
deficient for maternal Dnmt3L (Dnmt3L mKO), zygotic Dnmt3L (Dnmt3L zKO), or both maternal and
zygotic Dnmt3L (Dnmt3L mzKO) from blastocyst-stage embryos. We confirmed that Dnmt3L is a
positive regulator of DNA methylation and found no evidence that it antagonizes DNA methylation in
mESCs. While Dnmt3L mKO, as expected, mainly affected DNA methylation at imprinting control
regions (ICRs), Dnmt3L zKO cell lines showed moderate loss of methylation at many genomic regions
that are normally methylated by Dnmt3a. Interestingly, our results showed that Dnmt3L is critical for
maintaining the stability of Dnmt3a2, the predominant Dnmt3a protein product in ESCs, and that this
new role contributes to the effect of Dnmt3L on Dnmt3a-dependent DNA methylation.

3.2 RESULTS

Dnmt3L deficiency in mESCs results in hypomethylation at specific heterochromatin regions.
Genetic studies in mouse have demonstrated that maternal Dnmt3L is critical for DNA
methylation in oocytes, including the establishment of genomic imprints, whereas zygotic Dnmt3L is not
essential for mammalian development (42, 44, 171, 172). To better understand the roles of maternal and
zygotic Dnmt3L in DNA methylation, we derived mESC lines deficient for maternal Dnmt3L (Dnmt3L
mKO), zygotic Dnmt3L (Dnmt3L zKO, referred to as Dnmt3L KO for simplicity), or both maternal and
zygotic Dnmt3L (Dnmt3L mzKO), as well as wild-type (WT, Dnmt3L+/+) mESC lines, from blastocyststage embryos by breeding Dnmt3L-null homozygous (Dnmt3L-/-) or heterozygous (Dnmt3L+/-) females
with Dnmt3L+/- males (Figure 4A). Because female mESCs become hypomethylated in culture due to
upregulation of DUSP9, an X-linked MAPK phosphatase (173), we used male mESC lines (determined
by PCR amplification of Y-linked Sry) for subsequent experiments. The mESC lines were genotyped by
PCR and verified by Western blot analysis (Figure 4B).

42

Mammalian genomes contain different types of repetitive elements, including interspersed
transposable elements and tandemly arrayed satellite repeats, that consist of thousands of copies. For
instance, in the mouse genome, the major satellite (with a 234-bp unit), located at pericentromeric
heterochromatin, reaches up to 6 Mbp, and the minor satellite (with a 120-bp unit), located at
centromeric heterochromatin, goes up to 600,000 bp (174, 175). In general, repetitive sequences are
heavily methylated, and their methylation status can serve as an indicator of global DNA methylation. To
assess the impact of Dnmt3L deficiency on DNA methylation, we first compared the different mESC
lines for DNA methylation at the major and minor satellite repeats. Southern blot analysis of genomic
DNA digested with methylation-sensitive restriction enzymes revealed that Dnmt3L KO and Dnmt3L
mzKO mESC lines show substantial loss of methylation at the major satellite repeats, but no obvious
changes in methylation at the minor satellite repeats (Figure 4C-D). Consistent with previous reports that
maternal Dnmt3L is required for global DNA methylation in oocytes (171, 172), the female pronuclei of
zygotes derived from Dnmt3L-deficient oocytes were severely hypomethylated (Figure 5). However,
Dnmt3L mKO mESC lines showed normal levels of DNA methylation at the major satellite repeats
(Figure 4C), indicating that de novo methylation in Dnmt3L mKO embryos largely restored the
methylation levels (except special regions such as imprinted loci, see below) during the preimplantation
stage or during mESC derivation and culture. Taken together, our results show that zygotic Dnmt3L is
required for methylation at specific genomic regions in mESCs.
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Figure 4: Dnmt3L deficiency in mESCs results in hypomethylation at specific heterochromatin regions.
A. Mice matting strategies to generate mESCs with different genotypes. B. Confirmation of Dnmt3L
expression by western blot in different types of Dnmt3L-deficient mESCs, the numbers indicate the
clone numbers analyzed in each genotype. C and D. Southern blot analysis using methylation-sensitive
restriction enzymes on Dnmt3L-deficient mESCs clones using MaeII and major satellite repeat probe (C)
or HpaII and minor satellite repeat probe (D). DKO, Dnmt3a and Dnmt3b double knock-out mESC
clone.
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Figure 5: Zygotes derived from Dnmt3L-deficient female mice show global DNA hypomethylation.
A. Mice mating strategies to get Dnmt3L mKO and WT zygotes. PBs, polar bodies. B. 5-methylcytosine
(5mC) and 5-hydroxymethylcytosine (5hmC) staining of the zygotes. The male and female pronuclei, as
well as PBs, are indicated. Scale bars, 50 µM. This data was generated by Hongbo Zhao and is used with
her permission.

45

Dnmt3L is a positive regulator of DNA methylation in mESCs.
Contrary to biochemical, genetic and genomic evidence that Dnmt3L is a positive regulator of
DNA methylation (22, 42, 44, 166, 167, 171, 172, 176), Neri et al. recently reported that Dnmt3L
regulates DNA methylation both positively and negatively, depending on genomic regions (49). To
further understand the function and specificity of Dnmt3L in DNA methylation, we compared the DNA
methylation profiles of the different mESC lines (Dnmt3L+/+, Dnmt3L KO, Dnmt3L mKO, and Dnmt3L
mzKO) by reduced representation bisulfite sequencing (RRBS) analysis (177-179). For each genotype,
three independent cell lines (biological replicates) were included. For each cell line, we generated ~12-34
million high quality RRBS reads, of which ~8-23 million were uniquely aligned, containing ~454-679
thousand CpG sites with >=20-fold coverage. Reads from all cell lines showed near complete (>99%)
bisulfite conversion of cytosines in non-CpG contexts. In agreement with previous work (178), the
methylation levels of CpG sites displayed a bimodal distribution in WT mESCs, as well as in the
Dnmt3L-mutant cell lines, with most sites being either largely unmethylated (<20% methylation) or
largely methylated (>80% methylation) (Figure 6A-C, Figure 7).
We compared the Dnmt3L-mutant cell lines with WT mESCs for the methylation levels of CpG
sites, with the criteria for differentially methylated CpG sites being methylation difference >= 25% and q
value <= 0.01. While the vast majority (>99%) of CpG sites showed no significant changes in
methylation in all the Dnmt3L-mutant mESC lines, small factions of CpG sites were obviously
hypomethylated (Figure 2A-C). The patterns of the hypomethylated sites in Dnmt3L mKO and Dnmt3L
KO mESCs were different. In Dnmt3L mKO cells, fewer but more severely hypomethylated CpG sites
(387 sites, ~0.07% of all sites analyzed) were observed, most of which were within the imprinting
control regions (ICRs) of maternally imprinted genes (as expected, these sites were methylated at ~50%
in WT cells) (Figure 6A, D). In Dnmt3L KO cells, a larger number of CpG sites were hypomethylated,
mostly with moderate loss of methylation (4,281 sites, ~0.78% of all sites analyzed), and none of them
were in ICRs (Figure 6B). Dnmt3L mzKO cells exhibited combined changes of both Dnmt3L mKO and
Dnmt3L KO cells, with severe loss of methylation in CpG sites in ICRs and moderate hypomethylation
of many sites in other regions (Figure 6C). Our results indicate that maternal Dnmt3L is essential for the
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establishment of genomic imprints, consistent with previous studies (42, 44), but does not play a major
role in the methylation of other regions in mESCs, whereas zygotic Dnmt3L affects the methylation of a
subset of genomic regions, not including imprinted loci, in mESCs.
In sharp contrast to the report by Neri et al. that nearly 30% of the differentially methylated
regions (DMRs) show gain of methylation in shRNA-mediated Dnmt3L knockdown (KD) mESCs (49),
we observed only negligible numbers of hypermethylated CpG sites in the Dnmt3L-mutant mESC lines
(Figure 6A-C). Given that Neri et al. showed that Dnmt3L deficiency-induced gain of methylation occurs
mostly at promoter regions, it is unlikely that the discrepancy was due to the restricted coverage of
RRBS, as RRBS preferentially captures CG-rich sequences including many CpG islands and promoters.
Indeed, our RRBS data had good coverage of promoter regions (Figure 8D). We specifically searched
our RRBS data for the five hypermethylated promoter regions (Rhox5, Hoxa1, Cpne8, Enox1, and Zxda)
that Neri and colleagues verified by bisulfite sequencing (49) and found that 9 CpG sites in the Enox1
promoter had sufficient coverage (>=20) in both WT and Dnmt3L KO samples. However, our data
showed that almost all the sites had lower levels of methylation in Dnmt3L KO cells than in WT cells
(Figure 9).
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Figure 6: Dnmt3L is a positive regulator of DNA methylation in mESCs.
Scatter plots showing distribution of genome-wide DNA methylation by RRBS analysis using site
resolution in Dnmt3L mKO (A), KO (B) or mzKO (C) compared to WT mESCs. Hypomethylated sites
are shown in green, hypermethylated sites in blue, while sites located in ICRs in red. Unchanged sites are
in grey. D. ICRs with common hypomethylated sites for Dnmt3L mKO and mzKO mESCs. E.
Hypomethylated site overlap between Dnmt3L KO and mzKO mESCs. Panels D and E were prepared
with data generated by Sally Gaddis and were used with her permission. Scatter plots panels (A-C) were
generated by Sally Gaddis and were used with her permission.
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Figure 7. Frequency and percentage of CpG methylation per sample analyzed by RRBS.
Histograms representing the frequency and levels of CpG methylation in percentage per base from the
raw data of the three different biological replicates (mESCs clones) of each of the Dnmt3L genotype (i.e.
Dnmt3L WT, mKO, KO and mzKO) that were analyzed by RRBS. Histograms were generated by Yue
Lu and were used with her permission.
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Figure 8: Dnmt3L deficiency mainly affects Dnmt3a-methylated regions.
Scatter plots showing distribution of genome-wide DNA methylation by RRBS analysis using 500 bp tile
resolution in Dnmt3L mKO (A), KO (B) or mzKO (C) compared to WT mESCs. Hypomethylated tiles
are shown in green, hypermethylated tiles in blue, while tiles located in ICRs in red. Unchanged tiles are
in grey. D. Pie charts showing genomic distribution of hypomethylated tiles for Dnmt3L mKO, KO and
mzKO mESCs. E. Hypomethylated tile overlap between Dnmt3L KO (blue) and Dnmt3a KO (red)
mESCs. F. Hypomethylated tile overlap between Dnmt3L KO (blue) and Dnmt3b KO (green) mESCs.
Panels E and F were prepared with data generated by Sally Gaddis and were used with her permission.
Scatter plots panels (A-C) pie chart (D) were generated by Sally Gaddis and were used with her
permission.
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Figure 9. Differential methylation analysis between Dnmt3L KO and WT mESCs of the sites located
at the Enox1 promoter using RRBS data.
CpG-containing sites at the Enox1 promoter were found in the RRBS data from both Dnmt3L KO and
WT mESCs and their absolute levels of methylation in percentage were plotted. White circles, Dnmt3L
WT. Black squares, Dnmt3L KO.
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Neri et al. performed MeDIP-seq analysis to compare genome-wide DNA methylation in
Dnmt3L KD (shDnmt3L) and control (shGFP) mESCs, with only one sample in each group. By overlap
analysis, they designated the peaks unique to shGFP as loss-of-methylation regions (14,107 peaks), the
peaks unique to shDnmt3L as gain-of-methylation regions (5,724 peaks), and the overlapped peaks as
regions with no change in methylation (41,185 peaks) (49). To determine whether the DMRs are
statistically significant, we performed differential analysis of the data deposited by Neri and colleagues,
normalizing either by total number of mapped tags or by foreground tags (i.e. the tags in the peaks). At
FDR<=0.05 and FC>=2, our analysis confirmed most of the DMRs identified by Neri and colleagues. To
our surprise, however, almost all the DMRs turned out to be hypermethylated in Dnmt3L KD cells
(including many of the hypermethylated DMRs identified by Neri et al.), and almost none of the
hypomethylated DMRs reported by Neri et al. was significant (Figure 10A, B). This outcome is
essentially the opposite of our results using Dnmt3L KO mESCs (compare Figure 6B and Figure 10A-C)
and contradicts the results of many previous studies (42, 44-48, 171, 172, 180). The result that nearly all
DMRs are hypermethylated in Dnmt3L KD cells is also inconsistent with the conclusion of Neri and
colleagues that hypomethylated and hypermethylated regions account for ~70% and ~30%, respectively
(49). Flaws in their experimental design and data analysis may have contributed to the erroneous
conclusion reported by Neri and colleagues. Collectively, our results confirm that Dnmt3L functions as a
positive regulator of DNA methylation.
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Figure 10. Volcano plots of the MeDIP-Seq data from Neri et al. and the RRBS data from our work.
A. Hypothesized probability of the binomial test is determined by the total number of reads mapped to
the shDnmt3L and shGFP samples by Neri et al. B. Hypothesized probability of the binomial test is
determined by the number of reads mapped to all the merged peaks in the shDnmt3L and shGFP samples
by Neri et al. C. Dnmt3L KO vs WT RRBS by sites from our work. D. Dnmt3L KO vs WT RRBS by
500 bp tiles from our work. Volcano plots were generated by Yue Lu and were used with her permission.
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Dnmt3L deficiency mainly affects Dnmt3a-methylated regions.
Our previous work demonstrated that, although Dnmt3a and Dnmt3b redundantly methylate
many genomic regions in mESCs, they also have preferred and specific DNA targets. For example,
Dnmt3a is more efficient than Dnmt3b in methylating the major satellite repeats, whereas Dnmt3b
preferentially methylates the minor satellite repeats (32). Given that Dnmt3L KO mESCs showed overt
hypomethylation at the major satellite repeats but no changes in methylation at the minor satellite repeats
(Figure 4C, D), we postulated that zygotic Dnmt3L preferentially regulates the methylation of Dnmt3a
target regions in mESCs.
We recently performed genome-wide DNA methylation analysis of Dnmt3a KO mESCs and
Dnmt3b KO mESCs by whole-genome bisulfite sequencing (WGBS) (manuscript submitted). To test our
hypothesis that zygotic Dnmt3L mainly regulates Dnmt3a targets (rather than Dnmt3b targets) in
mESCs, we sought to compare the DNA methylation profile of Dnmt3L KO mESCs with the WGBS
datasets. For the comparisons, the RRBS data were first converted to 500-bp tiles. Again, Dnmt3L mKO
cells had only a small number of hypomethylated tiles, with the majority (23/30, ~77%) being in ICRs
and showing severe loss of methylation, Dnmt3L KO cells had ~10 times more hypomethylated tiles
(331), mostly with moderate loss of methylation, and Dnmt3L mzKO showed the combined changes,
whereas none of the cell lines had any hypermethylated tiles (Figure 8A-C). Analysis of the genomic
distribution of the hypomethylated tiles revealed that, in Dnmt3L mKO cells, nearly half of the them
were in promoters, consistent with their enrichment in ICRs, and in Dnmt3L KO and Dnmt3L mzKO
cells, they were mostly located in intergenic regions, gene bodies (introns and exons), and promoters
(Figure 8D). Overlap analysis showed that the vast majority (268/306, ~88%) of hypomethylated tiles in
Dnmt3L KO mESCs overlapped with those in Dnmt3a KO mESCs (Figure 8E), whereas a much lower
fraction (80/308, ~26%) of hypomethylated tiles in Dnmt3L KO cells overlapped with those in Dnmt3b
KO cells (Figure 8F). These results suggest that Dnmt3L is functionally more important for Dnmt3a than
for Dnmt3b in mESCs, in agreement with evidence obtained from genetic studies in mice (29, 35, 42,
44).
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Dnmt3a2 is unstable in the absence of Dnmt3L.
Biochemical studies indicate that Dnmt3L interacts with both Dnmt3a and Dnmt3b and
stimulates their catalytic activities (166, 167, 176, 181). Why Dnmt3L preferentially regulates Dnmt3amediated DNA methylation in vivo is an open question. To gain insights into the mechanism underlying
the functional specificity of Dnmt3L, we first analyzed the expression of the Dnmt proteins in Dnmt3Ldeficient mESCs by western blot. As compared to WT mESCs, Dnmt3L KO and mzKO mESCs, but not
Dnmt3L mKO mESCs, showed marked decreases in Dnmt3a2 and minor decreases in Dnmt3a1 and
Dnmt3b, whereas Dnmt1 was expressed at comparable levels in all the cell lines (Figure 11A). As
Dnmt3a2 is the predominant Dnmt3a isoform in mESCs (25), our data raised the possibility that
downregulation of Dnmt3a2 could contribute to the preferential effect on Dnmt3a targets observed in
Dnmt3L KO mESCs.
Transcription of the two Dnmt3a isoforms in mESCs - Dnmt3a1 (minor isoform) and Dnmt3a2
(major isoform) - was driven by different promoters (25). RT-qPCR analysis using specific primers
revealed that Dnmt3a1, Dnmt3a2 and total Dnmt3a, as well as Dnmt3b, mRNA levels were not altered in
Dnmt3L KO mESC lines (Figure 11B). These data suggest that post-transcriptional dysregulation led to
the decrease in Dnmt3a2 protein level in Dnmt3L KO mESCs.
Next, we examined whether Dnmt3a2 protein stability is affected in the absence of Dnmt3L. To
this end, we treated Dnmt3L KO and WT mESCs with the protein synthesis inhibitor cycloheximide
(CHX) and then monitored the rates of Dnmt3a2 decline over time. p53, a rapidly turning-over protein,
was used as a control for the efficacy of CHX treatment, and b-actin, a highly stable protein, was used as
a loading control. In the absence of Dnmt3L, Dnmt3a2 declined substantially more rapidly (Figure 11C).
By measuring the intensities of the Dnmt3a2 bands, we estimated that the half-life of Dnmt3a2 protein
was reduced to ~6 hours in Dnmt3L KO mESCs, as opposed to more than 12 hours in WT mESCs
(Figure 11D).
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Figure 11: Dnmt3a protein is unstable in the absence of Dnmt3L.
A. Western blot using different types Dnmt3L deficient mESCs, two clones per genotype. B. Upper
panel, diagram indicating the Dnmt3a locus (black) and the exons (white) of different Dnmt3a isoforms
indicating the position of the primers used for the analysis of mRNA levels by RT-qPCR. C. Analysis of
protein stability by treatment with cycloheximide (CHX) for different periods. D. Quantification of the
band intensity showed in C. E and F. Western blot results of inhibition of proteosomal (E) or lysosomal
(F) protein degradation pathways after treatment with MG132 or Baf-A1, respectively.
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Two major pathways - the ubiquitin-proteasome pathway and lysosomal proteolysis - mediate
protein degradation in eukaryotic cells. We therefore investigated whether these pathways were involved
in Dnmt3a2 degradation in the absence of Dnmt3L. We treated Dnmt3L KO and WT mESCs with the
proteasome inhibitor MG132 or the lysosome inhibitor Bafilomycin A1 (Baf-A1) for different periods of
time and then examined Dnmt3a2 levels by western blot analysis. Although the inhibitors were highly
effective, as evidenced by the dramatic accumulation of p53 and LC3B-II, respectively, they failed to
recover Dnmt3a2 levels in Dnmt3L KO mESCs (Figure 11E, F), suggesting that a different mechanism
was responsible for Dnmt3a2 degradation in these cells. Collectively, these results suggest that Dnmt3L
is required for Dnmt3a2 protein stability in mESCs.

The ability of Dnmt3L to interact with Dnmt3a is critical for Dnmt3a stability.
Biochemical and structural studies have shown that Dnmt3L and Dnmt3a directly interact via
their C-terminal regions (43, 170). We therefore hypothesized that formation of the Dnmt3L-Dnmt3a2
complex could lead to Dnmt3a2 stabilization. To test the hypothesis, we first sought to engineer a
Dnmt3L point mutation that abolishes Dnmt3L-Dnmt3a interaction by substituting phenylalanine 297 of
mouse Dnmt3L with aspartate (F297D). F297 (equivalent to F261 in human DNMT3L) is a critical
residue involved in interacting with Dnmt3a, and replacing this hydrophobic amino acid with the
negatively charged aspartate has been shown to abolish the ability of Dnmt3L to stimulate Dnmt3a
catalytic activity (43, 170). By co-immunoprecipitation (co-IP) experiments using Myc-tagged Dnmt3L
proteins transiently expressed in mESCs, we confirmed that WT Dnmt3L interacted with endogenous
Dnmt3a2 and that the F297D mutation disrupted the interaction (Figure 12A). We then performed rescue
experiments to compare the effects of WT Dnmt3L and the F297D mutant in restoring Dnmt3a2 levels in
Dnmt3L KO mESCs. To this end, Myc-tagged Dnmt3L or the F297D mutant was transfected in Dnmt3L
KO mESCs, and individual stable clones were obtained after 7-10 days of selection with blasticidin.
Notably, expression of WT Dnmt3L, but not the F297D mutant, resulted in obvious restoration of
Dnmt3a2 levels, as compared to stable clones transfected with the empty vector (Figure 12B). The
different effects could not be attributed to differences in expression levels of the Myc-tagged proteins, as
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both WT Dnmt3L and the F297D mutant were expressed at similar levels in the clones used in the
experiment (Figure 12B). To verify that formation of the Dnmt3L-Dnmt3a2 complex stabilized
Dnmt3a2, we again assessed Dnmt3a2 protein stability, as described above (Figure 11C-D), in the stable
clones reconstituted with Myc-tagged Dnmt3L proteins. Indeed, Dnmt3a2 stability almost completely
recovered in cells expressing WT Dnmt3L (half-life: ~12 hours), and the effect was not observed in cells
expressing the F297D mutant (Figure 12C-D). Southern blot analysis also confirmed that the DNA
methylation level at the major satellite repeats was rescued to a large extent in Dnmt3L KO mESCs
reconstituted with WT Dnmt3L, whereas expression of the F297D mutant protein had no effect (Figure
12E). Taken together, these results support our hypothesis that Dnmt3L, by interacting with Dnmt3a2 to
form a complex, makes Dnmt3a2 stable.
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Figure 12: The ability of Dnmt3L to interact with Dnmt3a is critical for Dnmt3a stability.
A. Western blot results of the co-immunoprecipitation experiment of Myc-Dnmt3L WT or F297D
mutant with endogenous Dnmt3a2. B. Western blot showing Dnmt3L KO stable rescue clones
overexpressing Myc-Dnmt3L WT, Myc-Dnmt3L F297D mutant or empty vector, result of three
representative clones per group. C. Analysis of protein stability in Dnmt3L KO stable rescue clones
overexpressing Myc-Dnmt3L WT or F297D mutant, by treatment with cycloheximide (CHX) for
different periods. D. Quantification of the band intensity showed in C. E. Southern blot results of major
satellite repeat with Dnmt3L KO stable rescue clones overexpressing Myc-Dnmt3L WT, Myc-Dnmt3L
F297D mutant or empty vector.
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Forced expression of Dnmt3a in Dnmt3L KO mESCs rescues DNA methylation.
Our data indicated that Dnmt3L plays a crucial role in maintaining Dnmt3a2 protein stability, in
addition to its role in stimulating Dnmt3a catalytic activity (166, 167, 176). The relative contributions of
these two regulatory effects of Dnmt3L in Dnmt3a-mediated DNA methylation are unclear. To
determine the functional importance of the regulation of Dnmt3a2 stability, we asked whether restoring
the Dnmt3a level in the absence of Dnmt3L would be sufficient to rescue DNA methylation. We
generated stable clones in Dnmt3L KO mESCs expressing Myc-tagged Dnmt3a1 or Dnmt3a2. We were
able to obtain Dnmt3a2 clones with expression levels similar to endogenous Dnmt3a2 level in WT
mESCs, although the expression levels in the Dnmt3a1 clones were lower (Figure 13A). Southern blot
analysis revealed that forced expression of either Dnmt3a1 or Dnmt3a2 substantially restored the
methylation levels at the major satellite repeats, although the rescue efficiency appeared to be slightly
lower than that of the WT Dnmt3L clone used in the experiment (Figure 13B). Thus, we conclude that
regulating Dnmt3a (especially Dnmt3a2) protein stability is an important aspect of Dnmt3L function that
significantly contributes to Dnmt3a-dependent DNA methylation in mESCs (Figure 13C).
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Figure 13: Forced expression of Dnmt3a in Dnmt3L KO mESCs rescues DNA methylation.
A. Western blot results showing Dnmt3L KO stable rescue clones overexpressing Myc-Dnmt3a1 or
Myc-Dnmt3a2. B. Southern blot results of major satellite repeat with Dnmt3L KO stable clones
overexpressing Myc-Dnmt3L WT, Myc-Dnmt3L F297D mutant, Myc-Dnmt3a1 or Myc-Dnmt3a2. C.
Model of the roles of Dnmt3L in the regulation of Dnmt3a activity in mESCs.
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3.3 DISCUSSION

Dnmt3L is a key regulator of de novo DNA methylation. Based on its ability to stimulate the
enzymatic activities of Dnmt3a and Dnmt3b in vitro (166, 167, 176), it is generally assumed that
Dnmt3L functions primarily as a catalytic cofactor of these enzymes. In the present study, we
demonstrate that, in mESCs, Dnmt3L also regulates the abundance of these de novo methyltransferases,
especially Dnmt3a2, the predominant Dnmt3a protein product in mESCs (25). Our results indicate that
Dnmt3L, via interacting with Dnmt3a2 to form a complex, stabilizes Dnmt3a2. Dnmt3L-deficient
mESCs show hypomethylation at genomic regions that are mainly Dnmt3a targets, including the major
satellite repeats. Restoring Dnmt3a amount (by forced expression of either Dnmt3a1 or Dnmt3a2) in
Dnmt3L-deficient mESCs largely rescues DNA methylation levels at the major satellite repeats. These
results suggest that Dnmt3L is not absolutely required for Dnmt3a-mediated methylation, at least at some
genomic regions, although it seems to enhance the methylation efficiency. Therefore, we conclude that
the regulatory roles of Dnmt3L on Dnmt3a activity and stability both contribute to Dnmt3a-dependent
DNA methylation and functions (Figure 13C).
During the mammalian life cycle, two waves of de novo DNA methylation take place – the first
occurring shortly after implantation, which establishes the initial methylation pattern in the embryo, and
the second occurring during germ cell maturation, which establishes germ line-specific methylation
marks, including genomic imprints (3, 164). Genetic studies and genome-wide DNA methylation
analysis suggest that Dnmt3b plays a major role in de novo methylation during embryogenesis (first
wave) and Dnmt3a is largely responsible for de novo methylation in germ cells (second wave) (29, 35,
171, 172, 182). Dnmt3L is essential for Dnmt3a-mediated methylation in germ cells but appears to be
dispensable for Dnmt3b-mediated methylation and functions during embryonic development (42, 44, 45,
171, 172). Our finding that Dnmt3L preferentially stabilizes Dnmt3a2 in mESCs provides a plausible
explanation for the functional specificity of Dnmt3L in vivo. Indeed, Dnmt3a2 and Dnmt3L are highly
expressed in prospermatogonia and growing oocytes (183, 184), the stages when active de novo DNA
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methylation occurs during gametogenesis. Further work is required to confirm the role of Dnmt3L in
maintaining Dnmt3a2 stability and the significance of this role in DNA methylation in the germ line.
It remains to be determined why Dnmt3L deficiency has a severe effect on Dnmt3a2 stability,
but only minor effects on Dnmt3a1 and Dnmt3b levels. While recombinant or exogenously expressed
Dnmt3a, Dnmt3b and Dnmt3L proteins are capable of interacting with each other (38, 166-168), there is
evidence that endogenous Dnmt3L physically interacts with Dnmt3a2, but not Dnmt3a1 and Dnmt3b, in
mESCs (48). This provides a possible explanation for the preferential effect of Dnmt3L on Dnmt3a2
stability. The full-length Dnmt3a1 and Dnmt3b proteins have high sequence homology except a variable
region at their N termini, and this region is absent in the shorter Dnmt3a2 isoform (25). However, this
variable region is unlikely to be directly involved in interacting with Dnmt3L, as structural evidence
indicates that the Dnmt3L-Dnmt3a2 interaction is mediated by their C-terminal regions (43). One
possibility for why endogenous Dnmt3a1 and Dnmt3b fail to form complexes with Dnmt3L in mESCs is
that they are less accessible to Dnmt3L. Dnmt3a1 and Dnmt3b are tightly associated with chromatin with
significant enrichment in heterochromatin, whereas Dnmt3a2 seems to be more loosely bound to
chromatin (25). That Dnmt3a2 is relatively more soluble and more widely distributed perhaps makes it
more susceptible to degradation in the absence of Dnmt3L. Alternatively, the extra sequences in the fulllength Dnmt3a1 and Dnmt3b proteins may protect them from being degraded by blocking the
degradation machinery. While the mechanism by which Dnmt3a2 is degraded remains to be elucidated,
our data suggest that it is independent of the ubiquitin-proteasome and lysosomal proteolysis pathways.
Another factor that needs to be considered is that, in mESCs, Dnmt3a2 is far more abundant than
Dnmt3a1 (25), which may make Dnmt3a2 more sensitive to the effects of Dnmt3L deficiency. Dnmt3b
is also abundantly expressed in mESCs. However, Dnmt3b produces multiple alternatively spliced
isoforms, some of which have no catalytic activity but may play regulatory roles in Dnmt3b-mediated
methylation (185), similar to the effects of Dnmt3L on Dnmt3a.
In agreement with previous studies regarding the role of Dnmt3L in DNA methylation in germ
cells, embryos and mESCs (42, 44-48, 171, 172, 180), our work shows that Dnmt3L is a positive
regulator of DNA methylation. This is in sharp contrast to a recent report by Neri et al., which concluded
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that, in mESCs, Dnmt3L regulates DNA methylation positively or negatively, depending on genomic
regions (49). However, their conclusion was not supported by convincing data, as re-analysis of the
MeDIP-seq data deposited by Neri and colleagues revealed that, surprisingly, shRNA-mediated Dnmt3L
depletion led to gain of methylation at many genomic regions, but almost no region with significant loss
of methylation, which would suggest that Dnmt3L functions predominantly as a negative regulator of
DNA methylation. Several factors may have contributed to the different conclusion drawn by Neri and
colleagues, including the limitations of MeDIP, lack of biological replicates, and flaws in data analysis.
Based on the outcome of our analysis of their data, as well as the way some of their data were presented
(e.g. Figure 4E in Neri et al.), we also cannot rule out the possibility that their samples or datasets were
switched.
In summary, we demonstrate in the present study that Dnmt3L plays a key role in stabilizing
Dnmt3a2 protein, in addition to its functions in the regulation of Dnmt3a catalytic activity and chromatin
targeting, and this new role likely contributes, to a large extent, to the functional specificity of Dnmt3L
in vivo (i.e. mainly affecting Dnmt3a-dependent methylation and functions).
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CHAPTER 4: Regulation of maintenance DNA methylation by PRMT6 in cancer

This chapter is based upon: Veland, N., Hardikar, S., Zhong, Y., Gayatri, S., Dan, J., Strahl, B.D.,
Rothbart, S.B., Bedford, M.T. and Chen, T. (2017) The Arginine Methyltransferase PRMT6 Regulates
DNA Methylation and Contributes to Global DNA Hypomethylation in Cancer. Cell Rep, 21, 33903397.

Used with permission of Elsevier.
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4.1 INTRODUCTION

In mammals, DNA methylation (5-methylcytosine, 5mC) is mostly restricted to CpG
dinucleotides and plays crucial roles in many biological processes. Aberrant DNA methylation patterns
are associated with cancer. Specifically, cancer cells generally exhibit global hypomethylation and locispecific hypermethylation, which are implicated in genomic instability and tumor suppressor silencing,
respectively (4). However, the mechanisms underlying these alterations remain largely unclear.
DNA methylation patterns are established by the de novo DNA methyltransferases DNMT3A
and DNMT3B and maintained primarily by the maintenance DNA methyltransferase DNMT1. DNMT1
recruitment to hemi-methylated CpG sites during DNA replication depends on UHRF1, a multi-domain
protein (50, 51). The SRA (SET- and RING-associated) domain of UHRF1 preferentially binds hemimethylated DNA and plays an important role in loading DNMT1 onto newly synthesized DNA (50, 51,
186). The RING domain-mediated ubiquitination of lysine residues in the N-terminal tail of histone H3
promotes DNMT1 association with H3 (67, 187, 188). Moreover, the TTD (tandem Tudor domain) and
PHD (plant homeodomain) cooperatively interact with the N-terminal tail of H3 by recognizing a
specific histone modification signature. Specifically, the TTD exhibits affinity for di- and tri-methylated
lysine 9 (H3K9me2/me3) (66, 186, 189), whereas PHD-mediated binding to H3 is disrupted by arginine
2 (H3R2) methylation (65, 190-192). Recent studies show that the SRA domain interaction with DNA
stimulates TTD-PHD-mediated H3 binding and that hemi-methylated DNA recognition allosterically
activates RING domain-mediated H3 ubiquitination (188, 193). These data suggest that UHRF1 targets
DNMT1 to newly replicated DNA through complex interactions with chromatin.
The observation that the UHRF1 PHD specifically binds unmodified, but not H3R2-methylated,
N-terminal tail of H3 suggests that DNA methylation may be modulated by H3R2 methylation. Arginine
methylation is carried out by the PRMT family, consisting of nine members (116). PRMT6 is the
primary enzyme responsible for asymmetric dimethylation of H3R2 (H3R2me2a) (68-70). Notably,
PRMT6 is frequently overexpressed in cancer cells and implicated in tumorigenic functions (113). In this
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study, we show that PRMT6 negatively regulates DNA methylation by impairing UHRF1 association
with chromatin and that its overexpression contributes to global DNA hypomethylation in cancer.

4.2 RESULTS

PRMT6 overexpression induces global DNA hypomethylation in mESCs
Given that H3R2 methylation disrupts UHRF1-H3 interaction (65, 190-192), we hypothesized
that PRMT6, the primary enzyme responsible for H3R2me2a, regulates DNA methylation. To test the
hypothesis, we generated mouse embryonic stem cell (mESC) clones overexpressing human PRMT6 by
stable transfection of a bicistronic vector expressing Myc-tagged PRMT6 and the blasticidin-resistant
gene (Figure 14A). mESCs offer an ideal experimental system for studying DNA methylation regulators,
as their survival and proliferation are not affected by DNA methylation loss (194). Western blots
detected increases in H3R2me2a that correlated with PRMT6 levels in the stable clones. Consistent with
previous reports that H3R2 methylation antagonizes H3K4me3 (68, 69, 135), H3K4me3 levels decreased
in clones expressing high levels of PRMT6. As controls, H3K9me3 and total H3 showed no alterations
(Figure 14B). Apparently, PRMT6 overexpression also led to increases in arginine methylation of nonhistone proteins (Figure 15A). The stable clones maintained the mESC state, as judged by colony
morphology, growth rates, and expression of the pluripotency factors Nanog, Sox2 and Oct4 (Figures
15B-D).
To assess the impact of PRMT6 overexpression on DNA methylation, we first analyzed the
minor satellite repeats (MSR) and intracisternal A-particle (IAP) retrotransposons. Southern blot analysis
of genomic DNA digested with the methylation-sensitive restriction enzyme HpaII revealed that cells
expressing Myc-PRMT6 exhibited drastic DNA hypomethylation compared to cells transfected with the
empty vector (mock) (Figures 14C and 14D). We then confirmed global DNA hypomethylation in
PRMT6-overexpressing mESCs with dot blot and immunofluorescence (IF) analyses using a 5mC
antibody (Figures 14E-14G). The effect of PRMT6 on DNA methylation depends on its catalytic
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activity, as an inactive PRMT6 mutant (E155Q) failed to induce DNA hypomethylation in mESCs
(Figures 16A-C). Together, these results demonstrate that PRMT6 and its methyltransferase activity
negatively regulates global DNA methylation, likely by inducing H3R2me2a.

PRMT6 overexpression impairs Uhrf1 association with chromatin
To determine the mechanism by which PRMT6 induces DNA hypomethylation, we first
examined the expression of Dnmts, as well as key regulators of DNA methylation, including Uhrf1
(murine Uhrf1 is also known as Np95), PCNA and Usp7. Western blots showed no changes in the levels
of these proteins in PRMT6-overexpressing cells (Figure 17A). We then investigated the possibility of
increased H3R2me2a affecting Uhrf1 binding to chromatin. Nuclear fractionation experiments revealed
that Uhrf1 chromatin association reduced dramatically in PRMT6-overexpressing mESCs compared to
mock mESCs (~10% vs. ~60%) (Figures 17B and 17C). Chromatin immunoprecipitation (ChIP) analysis
confirmed that increased H3R2me2a levels correlated with decreased Uhrf1 enrichment at MSR and IAP
regions in PRMT6-overexpressing mESCs (Figures 17D and 17E). These results support our hypothesis
that higher H3R2me2a levels induced by PRMT6 overexpression impair Uhrf1 association with
chromatin, resulting in a failure in maintaining DNA methylation.
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Figure 14. Overexpression of PRMT6 in mESCs induces global DNA hypomethylation.
A. Diagram of Myc-PRMT6 plasmid. B. Western blots showing the levels of Myc-PRMT6 and histone
marks in stable mESC clones. Mock, mESCs transfected with empty vector. Dnmt1-/-, Dnmt1 KO
mESCs. C and D. Southern blots showing DNA methylation at MSR (C) and IAP (D) after digestion of
genomic DNA with methylation-sensitive restriction enzyme HpaII. Uhrf1-/-, Uhrf1 KO mESCs. E. Dot
blot analysis of genomic DNA with 5mC antibody (left). The same membrane was stained with SYTOX
Green to verify equal DNA loading (right). F. Quantification of data in (E) by densitometry using Image
J. Shown are relative 5mC levels (mean + SD from three independent experiments). Paired t test was
used to determine statistical significance. **P < 0.01. G. IF analysis with 5mC antibody.
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Figure 15. PRMT6 overexpression results in increases in arginine methylation of some non-histone
proteins and shows no effect on mESC state.
A. Western blots using a pan-Rme2a antibody showing increases in arginine asymmetric dimethylation
of some proteins in mESCs overexpressing Myc-PRMT6. B. Representative images of mock-transfected
and Myc-PRMT6-overexpressing mESCs showing similar colony morphology. Scale bars, 50µm. C.
Western blots showing no changes in the expression of pluripotency factors Nanog, Sox2 and Oct4 in
Myc-PRMT6-overexpressing mESCs. D. IF analysis of co-cultured mock-transfected and Myc-PRMT6
overexpressing (indicated by arrows) mESCs, which confirms no changes in Nanog, Sox2 and Oct4
expression in PRMT6-overexpressing cells. Scale bars, 10µm.
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Figure 16. The catalytic activity of PRMT6 is required for its effect on DNA methylation.
A. In vitro methylation assay using PRMT6 proteins immunoprecipitated from mESC stable clones
expressing Myc-tagged WT PRMT6 or mutant PRMT6 (E155Q), which demonstrates that the E155Q
mutant is catalytically inactive. B and C. Southern blot analysis of IAP retrotransposons (B) or MSR
(minor satellite repeats) (C) after digestion of genomic DNA with the DNA methylation-sensitive
restriction enzyme HpaII, which shows hypomethylation in mESC clones overexpressing WT PRMT6,
but not the inactive E155Q mutant.
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Figure 17. Uhrf1 chromatin association is impaired in mESCs overexpressing PRMT6.
A. Western blots showing the levels of DNA methylation enzymes and regulators. Note that mESCs
express two major Dnmt3a isoforms (Dnmt3a and Dnmt3a2) and that the Dnmt3a antibody cross-reacts
with Dnmt3b. B. Nuclear fractionation assay showing Uhrf1 chromatin association. PCNA and HP1α
were used as controls for soluble and chromatin-associated proteins, respectively. Total, nuclei directly
dissolved in 2xSDS loading buffer. C. Quantification of data in (B) by densitometry using Image J.
Shown are percentages of soluble and chromatin-associated Uhrf1 in each sample (mean + SD from
three independent experiments). D and E. ChIP assays showing relative enrichment of H3R2me2a (D)
and Uhrf1 (E) at MSR and IAP regions (mean + SD from three independent experiments).
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PRMT6 upregulation correlates with DNA hypomethylation in human cancers
Global DNA hypomethylation is a hallmark of cancer cells (4), but the underlying mechanisms
are poorly understood. Given that overexpression of PRMT6 is reported in multiple types of cancer
(113), we postulated that PRMT6 upregulation might contribute to global DNA hypomethylation in
cancer.
We first assessed the correlation between PRMT6 expression and DNA methylation in a panel of
cancer cell lines. Western blots indicated that, compared to non-tumorigenic breast cell lines 76NF2V
and MCF 10F, most cancer cell lines examined exhibited upregulation of PRMT6, although the levels
varied greatly (Figure 18A). The 5mC content in the cancer cell lines was measured by liquid
chromatography and tandem mass spectrometry (LC-MS/MS) (Table 3). Based on the relative levels of
PRMT6 (Figure 18A), we divided the cancer cell lines into two groups: the PRMT6-high group had
significantly lower levels of 5mC than the PRMT6-low group (Figure 18B).
We next asked whether PRMT6 upregulation correlates with DNA hypomethylation in primary
tumor samples by employing The Cancer Genome Atlas (TCGA) database. Data downloaded from the
cBioPortal for Cancer Genomics showed wide variations in PRMT6 expression in all cancer types
(Figure 19A). We selected three common cancer types, i.e. breast cancer, lung cancer and colorectal
cancer, because a large amount of DNA methylation data is available in the TCGA database. When all
samples of each cancer type were included in the analyses, no clear correlation was observed between
PRMT6 expression and DNA methylation levels, which is not surprising because both PRMT6 and DNA
methylation levels are highly variable in different samples. However, comparisons of the samples with
the highest 20% and lowest 20% of PRMT6 expression revealed a significant inverse correlation
between PRMT6 expression and DNA methylation in lung cancer and colorectal cancer, but not in breast
cancer (Figure 18C). Based on our hypothesis, DNA methylation may not be affected by PRMT6 if
UHRF1 expression is low. Therefore, we first divided the samples into UHRF1-high (upper 70%) and
UHRF1-low (lower 30%) groups and then compared DNA methylation levels in samples with high (top
20%) and low (bottom 20%) PRMT6 expression. Consistent with our hypothesis, we observed a
significant inverse correlation between PRMT6 expression and DNA methylation in the UHRF1-high
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groups of all three cancer types (Figure 18D upper panel) and no correlations in the UHRF1-low groups
(Figure 18D lower panel). Together, these data suggest that PRMT6 upregulation contributes to global
DNA hypomethylation in cancer.

PRMT6 depletion or inhibition restores global DNA methylation in MCF7 cells
To validate the significance of PRMT6 upregulation in DNA hypomethylation, we assessed the
impact of PRMT6 knockdown (KD) and inhibition in MCF7 cells, a breast cancer cell line with high
PRMT6 expression (Figure 18A). Stable expression of PRMT6 shRNAs, which efficiently depleted
PRMT6 (Figure 20A), or treatment with MS023, a PRMT inhibitor that is potent for PRMT6 (147),
resulted in substantial decreases in H3R2me2a, but no changes in DNMT1 and UHRF1 levels (Figures
20A and 20C). Consistent with previous reports (140-142, 145, 147), PRMT6 KD or MS023 treatment
resulted in defects in MCF7 proliferation (Figures 21A-D). Dot blot analysis showed that PRMT6
depletion or inhibition led to increases in global DNA methylation (Figures 20B and 20D). We verified
the results by bisulfite sequencing analysis of a region in the 45S ribosomal DNA (rDNA) promoter,
which is partially methylated in MCF7 cells (195). Indeed, PRMT6 KD or MS023-treated cells had
markedly higher levels of DNA methylation (~90%) than control cells (~60%) (Figure 20E). Both de
novo and maintenance methylation probably contributed to the restoration of DNA methylation levels.
In agreement with our hypothesis, UHRF1 chromatin association was substantially enhanced in
cells treated with MS023 (as opposed to ~50% chromatin association in cells treated with DMSO)
(Figures 20F and 20G). To strengthen the hypothesis, we analyzed the UHRF1 occupancy at the
promoter regions of three PRMT6 target genes, HOXA2, CDKN1A and GREB1C (69, 139, 140, 142).
ChIP and methylated-DNA immunoprecipitation (MeDIP) analyses confirmed that H3R2me2a reduction
induced by MS023 correlated with increases in UHRF1 enrichment and DNA methylation levels at these
loci (Figures 20H-20J). Collectively, these results suggest that, in MCF7 cells, increased H3R2me2a due
to PRMT6 upregulation plays a critical role in inducing global DNA hypomethylation by impairing
UHRF1 chromatin binding.
74

75

Figure 18. PRMT6 expression inversely correlates with DNA methylation in human cancer cells.
A. Western blots showing PRMT6 levels in human cancer cell lines. BR NT, breast non-tumorigenic;
BRCA, breast cancer; PCA, prostate cancer; COAD, colorectal adenocarcinoma; LUAD, lung
adenocarcinoma; NB, neuroblastoma; OS, osteosarcoma. B. Comparison between PRMT6-high and
PRMT6-low cell lines for total 5mC levels (determined by LC-MS/MS, see Table 3). C and D.
Correlation of PRMT6 expression and DNA methylation data from the TCGA database. The mean DNA
methylation levels between cancer samples with the highest (top 20%) and lowest (bottom 20%) PRMT6
expression in each cancer type were compared, either without considering UHRF1 expression (C) or by
dividing all samples into UHRF1-high (upper 70%) and UHRF1-low (lower 30%) groups before analysis
(D). Note that the 30% cutoff for UHRF1 expression was based on samples of all three cancer types
combined and, therefore, the sample sizes of UHRF1-high and UHRF1-low groups in each cancer type
do not account for precisely 70% and 30%. Wilcoxon rank sum non-parametric test with two-tailed P
values was used to determine the significance of differences in (B-D). See also Table 3 and Figure 19.
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Table 3: 5mC content in human cancer cell lines.

Cell line

Experiment 1

Experiment 2

Mean

5mdC/(dC+5mdC)

Mean ± SD
(%)

MDA-MB 231

0.0488

0.0524

0.0506

5.06 ± 0.26

MDA-MB 361

0.0668

0.0721

0.0695

6.95 ± 0.37

MDA-MB 436

0.0721

0.0744

0.0733

7.33 ± 0.16

MDA-MB 468

0.0659

0.0686

0.0672

6.72 ± 0.19

HCC-1569

0.0608

0.0663

0.0636

6.36 ± 0.39

HCC-1599

0.0590

0.0593

0.0592

5.92 ± 0.02

HCC-1806

0.0506

0.0539

0.0523

5.23 ± 0.23

HCC-1937

0.0690

0.0753

0.0722

7.22 ± 0.45

MCF7

0.0548

0.0559

0.0553

5.53 ± 0.07

SKBR3

0.0494

0.0510

0.0502

5.02 ± 0.11

BT-474

0.0730

0.0774

0.0752

7.52 ± 0.31

DU-145

0.0728

0.0775

0.0751

7.51 ± 0.34

LnCaP

0.0403

0.0414

0.0409

4.09 ± 0.08

PC-3

0.0631

0.0659

0.0645

6.45 ± 0.19

HCT-116

0.0736

0.0785

0.0760

7.60 ± 0.34

RKO

0.0657

0.0675

0.0666

6.66 ± 0.13

H82

0.0636

0.0638

0.0637

6.37± 0.02

H526

0.0575

0.0589

0.0582

5.82 ± 0.10

VMRC-LCD

0.0583

0.0587

0.0585

5.85 ± 0.03

SH-SY5Y

0.0584

0.0603

0.0593

5.93 ± 0.13

U2OS

0.0587

0.0618

0.0603

6.03 ± 0.22

The 5mC content in each cell line was quantified by liquid chromatography-tandem mass
spectrometry (LC-MS/MS). Shown are results from two independent experiments. The 5mC content is
shown as a percentage of the total cytosine pool according to peak areas: 5mdC/(dC+5mdC) x 100%.
SD, standard deviation.
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Figure 19. PRMT6 expression and correlation with DNA methylation in cancer samples from TCGA
database.
A. Relative expression of PRMT6 in cancer samples in the TCGA database (from cBioPortal for Cancer
Genomics). B. Correlation of PRMT6 expression and DNA methylation data in the TCGA database.
BRCA, breast cancer; LUAD, lung adenocarcinoma; COAD, colorectal adenocarcinoma. Wilcoxon rank
sum non-parametric test with two-tailed P values was used to determine the differences in DNA
methylation levels between cancer samples with the highest (top 10%) and lowest (bottom 10%) PRMT6
expression levels in each cancer type.
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See Figure 20 legend in next page.
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Figure 20. PRMT6 depletion or inhibition restores DNA methylation in MCF7 cells.
A and C. Western blot analysis of MCF7 cells stably transfected with PRMT6 shRNAs (A) or treated
with MS023 (10 µM for 4 days) (C). B and D. Dot blot analysis of samples in (A) and (C), respectively,
with 5mC antibody. DNA loading was verified by SYTOX Green staining. E. Bisulfite sequencing
analysis of 45S rDNA promoter region containing 27 CpG sites. Open circles, unmethylated CpGs;
Filled circles, methylated CpGs. F. Nuclear fractionation of MCF7 cells treated with MS023 for UHRF1
chromatin association. PCNA and HP1α were used as controls for soluble and chromatin-associated
proteins, respectively. G. Quantification of data in (F) by densitometry using Image J. Shown are
percentages of soluble and chromatin-associated UHRF1 in each sample (mean + SD from three
independent experiments). H-J. ChIP assays or MeDIP assays showing relative enrichment of
H3R2me2a (H) and UHRF1 (I) or relative DNA methylation levels (J) at HOXA2, CDKN1A and
GREB1C promoter regions (mean + SD from three independent experiments). See also Figure 21.
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See Figure 21 legend in next page.
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Figure 21. PRMT6 knockdown or inhibition in MCF7 cells leads to defects in cell proliferation.
A and B. MCF7 cells stably transfected with control or PRMT6 shRNAs were cultured for 12 days
(starting at 104 per well), and the cells were visualized daily and counted every 4 days. Shown are
representative images on day 10 (A) and the growth curves (B). Scale bars in (A), 50 µm. C and D.
MCF7 cells were cultured in the presence of DMSO or MS023 (10 µM) for 10 days (starting at 105 per
well), and the cells were visualized daily and counted every other day. Shown are representative images
on day 4 and day 9 (C) and the growth curves (D). Scale bars in (C), 50 µm.
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4.3 DISCUSSION

Various epigenetic mechanisms act cooperatively in regulating chromatin structure and gene
activity. While it has been well established that DNA methylation and several histone modifications,
notably lysine methylation, are functionally linked (189, 196), much less clear is the crosstalk between
DNA methylation and arginine methylation. In this study, we demonstrate that PRMT6 is a negative
regulator of DNA methylation. We show that overexpression of PRMT6 in mESCs compromises Uhrf1
association with chromatin. Consistent with biochemical and structural evidence that H3R2 methylation
inhibits Uhrf1-H3 interaction (65, 66, 190-192), our results indicate that the catalytic activity of PRMT6
is required for its effect on DNA methylation. Thus, we propose that PRMT6, by generating H3R2me2a,
impairs recruitment of the Dnmt1-Uhrf1 complex to newly replicated DNA, resulting in passive DNA
demethylation. However, we cannot rule out the possibility that PRMT6-mediated methylation of other
arginine residues on histone or non-histone proteins also contributes to DNA methylation changes. Our
work uncovers a novel regulatory mechanism involved in the maintenance of DNA methylation.
While the relevance of PRMT6 in regulating DNA methylation in normal developmental and
cellular processes remains to be determined, we provide evidence that PRMT6 overexpression
contributes to global DNA hypomethylation in cancer cells. We show that PRMT6 expression levels
inversely correlate with DNA methylation levels in both cancer cell lines and primary cancer tissues.
Moreover, depletion or inhibition of PRMT6 leads to restoration of DNA methylation levels in MCF7
cells, suggesting a causal link between PRMT6 overexpression and DNA hypomethylation. It is worth
noting that, while most PRMT6 high-expressing cell lines have relatively low levels of DNA
methylation, some cell lines that are severely hypomethylated (e.g., MDA-MB 231, SKBR3) show no
obvious PRMT6 upregulation (Figure 18A and Table 3), suggesting that multiple mechanisms are
involved in DNA hypomethylation in cancer. Some of the mechanisms likely affect the functionality of
the DNMT1-UHRF1 complex. UHRF1 could positively or negatively impact DNA methylation. On the
one hand, UHRF1 is essential for DNMT1 recruitment to newly replicated DNA to maintain DNA
methylation (50, 51). On the other hand, UHRF1, an E3 ubiquitin ligase, has been shown to ubiquitinate
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UHRF1 itself, DNMT1 and DNMT3A, leading to their degradation (104, 106-108). UHRF1 is highly
expressed in many cancers (113), which likely contributes to DNA methylation changes. Indeed,
overexpression of human UHRF1 in zebrafish hepatocytes leads to Dnmt1 mislocalization and
degradation, DNA hypomethylation, and hepatocellular carcinoma (109).
PRMT6 is overexpressed in multiple types of cancer. In breast cancer, PRMT6 levels positively
correlate with tumor stages, suggesting that PRMT6 may contribute to tumor progression (140).
Nevertheless, we observed that the benign breast cancer cell line MCF7 has higher levels of PRMT6 than
the aggressive cell line MDA-MB 231 (Figure 18A), indicating that the relationship between PRMT6
expression and cancer invasiveness is complex. These differences could be attributed to the different
cancer subtypes that they represent. How PRMT6 overexpression contributes to tumorigenesis remains
to be determined. PRMT6 generally functions as a transcriptional repressor, although it has also been
shown to act as a co-activator of nuclear receptors such as estrogen receptor (113). In this study, we
demonstrate that PRMT6 contributes to DNA hypomethylation, which is another characteristic
associated with cancer as it could lead to genomic instability and expression of cancer-promoting genes.
Importantly, the effect of PRMT6 on DNA methylation is reversible, as depletion or inhibition of
PRMT6 restores DNA methylation levels in MCF7 cells. This raises the possibility of targeting PRMT6
for specific cancer therapy. However, it remains to be determined to what extent PRMT6-dependent
DNA hypomethylation contributes to tumorigenesis and maintenance of the tumor phenotype.
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CHAPTER 5: Regulation of DNMT1 in intestinal stem cells
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5.1 INTRODUCTION

After the establishment of DNA methylation patterns during early embryonic development by de
novo DNMTs, these patterns are largely maintained by DNMT1 during differentiation of somatic cells,
although some loci-specific changes occur in a cell-type specific manner. These DNA methylation
changes are important for developmental progression and cell lineage choice, as DNA methylation is a
critical component of the regulatory network that controls the gene expression program that drives proper
differentiation and maintains the differentiated states (3). In postnatal mammals, DNA methylation is
generally stable in most somatic tissues but shows dynamic changes in tissues with high proliferation
rates such as the intestine, skin and hematopoietic compartments. In these tissues, somatic or “adult”
stem cells are fundamental to maintaining tissue homeostasis, as they undergo constant proliferation,
self-renewal and differentiation to give rise to the diverse cell types that form the tissue (197). The
balance between adult stem cell self-renewal and differentiation is a complex process that involves
various epigenetic mechanisms, including DNA methylation (93, 198-200), and its disruption is
associated with development of diseases, including cancer. However, how DNA methylation is regulated
in adult stem cells and its roles in self-renewal and differentiation are poorly understood.
The high cell turnover of the intestinal epithelial tissue makes it an ideal system to study adult
stem cell functions in tissue regeneration, as well as the molecular mechanisms that regulate their selfrenewal and differentiation for the maintenance of tissue homeostasis. This tissue is sustained by the
presence of intestinal stem cells (ISCs) that reside at the bottom of the intestinal crypts, which are
proliferative units embedded in the wall of the intestine (197, 201). Studies in mouse intestinal
epithelium revealed that DNA methylation is required for its development. For example, Dnmt1, the
highest expressed DNMT in small intestine, is essential for perinatal development of intestinal epithelial
progenitors in mice, as its loss results in impaired proliferation, global DNA hypomethylation, DNA
damage and apoptosis, leading to loss of villi and, ultimately, postnatal lethality (202, 203). Similarly, it
has been shown that inactivation of the DNMT1 gene in the human colon cancer cell line HCT116 results
in global DNA hypomethylation, increased genomic instability and severe mitotic defects that ultimately
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triggers apoptosis (63). In contrast, Dnmt1 function is different in adult small intestine, as its conditional
deletion in adult ISCs results in expansion of intestinal crypts and aberrant gene expression (203, 204).
Moreover, genome-wide DNA methylation analysis in ISCs showed dynamic DNA methylation at
enhancers that regulate critical genes for stem cell self-renewal and differentiation, which is associated
with transcription factor binding (204-206). Notably, one study showed that Dnmt1 is required to
maintain the gained DNA methylation at specific ISCs enhancers upon differentiation, such as the ones
that regulate expression of the genes Olfm4 and Hes1 (204). The striking differences observed in the
mouse phenotypes after Dnmt1 deletion in perinatal progenitors compared to adult ISCs are partially due
to the compensatory effect of Dnmt3b upregulation after Dnmt1 deletion in adult crypts (207), as in the
absence of Dnmt1, crypts cells require Dnmt3b for their survival. Indeed, combined deficiency of Dnmt1
and Dnmt3b results in increased DNA damage and apoptosis, leading to severe crypt and villi
degeneration (207).
Therefore, it is important to understand the role of DNA methylation in the balance between
ISCs self-renewal and differentiation, as well as the molecular mechanisms that regulate its function.
This is highly relevant to human diseases, as dysregulation of these epigenetic mechanisms contributes to
the development of gut disorders, like inflammatory diseases and colon cancer (201). In fact, multiple
studies have associated aberrant DNA methylation in ISCs with the development of colon cancer (75, 77,
208, 209). In this study, I discovered that intestinal crypts specifically express a shorter Dnmt1 protein
product, which results from an endoproteolytic cleavage event. To our knowledge, this is the first
example of a cleavage event as a regulatory mechanism of the DNA methylation machinery. Although
the data are preliminary, better understanding of the functional relevance of this particular processing
event, as well as the molecular mechanisms involved, could provide important insights into the
regulation and functions of DNA methylation in ISCs.
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5.2 RESULTS AND DISCUSSION
Mouse intestine express a short Dnmt1 protein product
Other than a few proteins such as Uhrf1 and PCNA, the players that regulate Dnmt1 activity and
functions are largely unknown, partly because commercial Dnmt1 antibodies are not specific or not
efficient for some applications (e.g. immunoprecipitation). In order to facilitate the study of Dnmt1
regulation in mouse tissues, we generated a Flag-Dnmt1 knock-in (KI) mouse by gene targeting,
whereby a 3XFlag tag was introduced in exon 4 of Dnmt1, right after the initiation codon of Dnmt1o
(Figure 22A). We expected that Dnmt1o would be tagged in oocytes and the full-length Dnmt1 would be
tagged in somatic tissues. After obtaining mESC clones containing the correctly targeted allele, they
were introduced into receiver blastocysts to derive chimeric mice, which were then crossed with
C57BL/6J mice to obtain germline transmission of the targeted allele. Deletion of the floxed IRES-bGeo
selection cassette, resulting in the functional Flag-Dnmt1 KI allele, was achieved by crossing with Zp3Cre mice (Figure 22A).
In order to validate the expression of Flag-Dnmt1 in adult tissues, we performed western blot
analysis using Flag antibody on whole protein extracts from different mouse tissues (ovary, liver, brain,
colon, small intestine and lung) obtained from heterozygous KI mice and used wild-type mice tissues as
controls. Unexpectedly, we were not able to detect Flag-Dnmt1 protein in small intestine (here after
referred as intestine for simplicity), although it was detected in the other tissues analyzed (Figure 22B).
Surprisingly, when we probed the same membrane with an antibody that recognizes endogenous Dnmt1,
we observed a strong band of a significantly smaller size (~160 kDa) in intestine compared to the fulllength Dnmt1 protein band (~210 kDa) observed in the rest of the tissues analyzed. Importantly, using
the antibody specific for endogenous Dnmt1, we identified the same protein band in intestine obtained
from wild-type mouse (Figure 5.1 B). This result indicates that the presence of the smaller Dnmt1 protein
band is not an experimental artifact that resulted from the gene-targeting strategy and instead suggests
that a smaller Dnmt1 protein product, which lacks part of the N-terminal region including the sequence
encoded by exon 4, is specifically present in intestine.
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Figure 22: Generation of Flag-Dnmt1 KI allele and detection of a short Dnmt1 protein in small intestine.
A. Gene-targeting strategy for knocking in a 3XFlag tag (in red) in exon 4 of Dnmt1, right after the
initiation codon (ATG) for Dnmt1o. Dnmt1 exons are indicated by black boxes. LoxP sites are indicated
by black triangles. The IRES-bGeo selection cassette is also shown. Cre-mediated recombination to
delete the selection cassette results in the generation of the active KI allele. B. Confirmation of the
expression of FLAG-Dnmt1 in different tissues of the KI mouse by western blot using Flag tag antibody.
Detection of short Dnmt1 in small intestine is shown using endogenous Dnmt1 antibody, while b-actin is
used as loading control.
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The short Dnmt1 protein is not due to alternative splicing or different translation start site usage
To determine what level of regulation gives rise to the intestine-specific small Dnmt1 protein
product, we first investigate whether the short Dnmt1 results from alternative mRNA splicing. To this
end, we isolated total RNA from purified intestinal crypts, as well as from mESCs as a control, and
detected by RT-qPCR the presence of transcripts containing different exons encoding amino acids
located at the N-terminal region of Dnmt1. We designed primer pairs to amplify fragments covering
exons 4 to 6, or 5 to 8, and as control we amplified fragments covering exons 25 and 26 located in the
middle of Dnmt1 protein and exons 33 and 34 located at the C-terminal region of the protein (Figure
23A). Our results indicate that all the exons examined were detected in mRNA from intestinal crypts, as
well as from mESCs (Figure 23B). We confirmed by sequencing that Dnmt1 mRNA transcripts from
intestinal crypts and mESCs were identical. Together, our data indicates that the short Dnmt1 protein
product does not result from alternative mRNA splicing.
Dnmt1o, the oocyte-specific isoform, originates from alternative promoter usage and, as a result,
a downstream AUG in exon 4 is used as the translation initiation codon, which results in the lack of 118
amino acids at the N terminus of the full-length DNMT1 (Figure 23A). We therefore investigated
whether the usage of a downsteam translation initiation codon would produce the small Dnmt1 protein
detected in intestine. To this end, we generated four different constructs using downstream AUG codons
with potential Kozak sequences as the translation initiation sites. We expressed these N-terminally
truncated Dnmt1 proteins in Dnmt1 KO mESCs and compared their protein sizes with that of the short
Dnmt1 product in intestine by western blot. As shown in Figure 23C, all the constructs generated protein
products that were smaller than the short Dnmt1 protein observed in intestinal crypts. These results
indicate that it is unlikely that the intestine-specific short Dnmt1 protein product is generated by the
usage of an alternative translation initiation codon.
To determine whether the KI allele produces any Flag-tagged protein product in intestine, we
performed immunohistochemistry analysis of intestine tissue sections from a Flag-Dnmt1 KI
homozygous mouse using a Flag antibody, which detected signal in the intestinal crypts (Figure 23D, left
panel). The position of the Flag-positive cells in the crypts indicates that these cells are composed of
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ISCs (green arrowheads) and transient-amplifying (TA) progenitors (red arrowheads), consistent with the
fact these are proliferative populations that express high levels of Dnmt1 (204). Importantly, the cell
localization patterns detected with the Flag immunohistochemistry staining was highly similar to the
patterns observed in the staining of wild-type intestine with an antibody for endogenous Dnmt1, which
recognizes an epitope located at the middle of the protein (Figure 23D, right panel). Together, these
results indicates that the missing N-terminal protein fragment from intestinal Dnmt1 is likely present in
the intestinal crypts of Flag-Dnmt1 KI mouse, suggesting that the smaller Dnmt1 protein, which lacks
this fragment, may result from post-translational processing of the full-length Dnmt1 in these cells.
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Figure 23: Short intestinal Dnmt1 is not due to alternative splicing or different translation start site usage.
A. Diagram of mouse Dnmt1 protein indicating domains and position of exons analyzed by RT-qPCR. B.
RT-qPCR results showing the presence of the indicated exons in Dnmt1 mRNA from intestinal crypts
compared to mESCs. C. Western blot indicating that the truncated Dnmt1 proteins generated from
potential downstream translation start sites are smaller than the Dnmt1 product detected in intestine. D.
Immunohistochemistry analysis of intestine sections with Flag and Dnmt1 antibodies showing both Flag
and Dnmt1 signals in intestinal crypts. Green arrowheads, ISCs. Red arrowheads, TA cells.
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The intestinal Dnmt1 protein product is generated by an endoproteolytic cleavage event.
Our data indicated that the intestinal short Dnmt1 protein was not produced by alternative
mRNA splicing or alternative translation initiation codon usage. Moreover, analysis of Dnmt1
localization in the intestinal crypts suggested that the N-terminal fragment containing the Flag tag was
present in cells that express Dnmt1 (Figure 23). Based on these data, we hypothesized that the smaller
intestinal Dnmt1 could be caused by a post-translational processing event, such as endoproteolytic
cleavage. To test this hypothesis, we examined for the presence of small protein fragments by western
blot using different antibodies that recognize epitopes located in the N-terminal or middle region of
Dnmt1, as well as Flag antibody. For this analysis, we compared intestinal crypts purified from wild-type
mouse, with intestine and colon tissue from a Flag-Dnmt1 KI homozygous mouse. As a control, we used
full-length Dnmt1 expressed in Dnmt1 KO mESCs. Our results confirmed that both purified intestinal
crypts and intestine tissue had the short Dnmt1 protein, as the ~160-kDa protein band was detected in
both samples using the antibody that recognizes the middle region of Dnmt1 (Figure 24A, left panel). In
contrast, colon tissue showed a band of the corresponding size of full-length Dnmt1 (~210 kDa), as
observed in mESCs expressing Dnmt1 full-length protein. Notably, western blot analysis using the
antibody that recognizes the N-terminal region of the Dnmt1 revealed that the samples corresponding to
intestinal crypts and intestine tissue also had the protein band corresponding to the size of full-length
Dnmt1, although their levels were lower compared to colon or mESCs (Figure 24A, right panel).
Importantly, a small protein fragment of ~50 KDa was detected using this antibody in crypts, intestine
and colon samples (Figure 24A, right panel). Similar results were obtained using Flag antibody (Figure
24A, middle panel). Taken together, these results indicate that Dnmt1 undergoes an endoproteolytic
cleavage event that results in the short Dnmt1 protein product of ~160 KDa and an N-terminal protein
fragment of ~50 KDa in intestine and, to a lesser extent, in colon.
The western blot and immunohistochemistry results suggest that both uncleaved full-length and
cleaved Dnmt1 proteins are present in cells at intestinal crypts. Different possibilities can be envisioned
regarding the functionality. For example, it is possible that the Dnmt1 protein is not immediately cleaved
after protein synthesis and thus it resides in the cells for certain period of time, until the cleavage event
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occurs as part of an unknown regulatory mechanism. A second possibility, which is not mutually
exclusive from the first possibility, is that the short N-terminal protein fragment that results from the
Dnmt1 cleavage event may have its own unidentified biological function. The second possibility is
particularly intriguing, given that the small N-terminal fragment is relatively stable rather than being
further processed and rapidly degraded. There are some documented examples that protein fragments
have independent and different functions from the original protein from where they originate. For
example, TET2 has lost its CXXC domain during evolution, as a result of a chromosomal inversion event
that has converted a portion of the ancestral TET2 gene into a separate gene, IDAX, which encodes a
protein containing the original CXXC domain. IDAX binds unmethylated CpG sequences via its CXXC
domain, localizes at CGIs, and physically interacts with TET2, suggesting that it may play a role in
recruiting TET2 to its genomic targets (210). Although this is strictly not a similar case as with intestinal
Dnmt1, it is possible that evolution has found a different way of generating a protein fragment with
possible regulatory functions by cleaving the N-terminal region of Dnmt1. However, the functional
significance of this cleavage event requires further investigation.
An important step to determine the functional significance of Dnmt1 cleavage in intestine is to
elucidate the molecular mechanism underlying this processing event. To this end, we first aimed to
identify the precise site and amino acid motif sequence where the cleavage event occurs. For this
purpose, we immunoprecipitated both the full-length Flag-Dnmt1 and the cleaved N-terminal Flagfragment from intestinal crypts purified from Flag-Dnmt1 KI homozygous mouse (Figure 24B) and
submitted the samples for mass spectrometry analysis. Mapping of the peptides identified from the fulllength Flag-Dnmt1 indicated that 94 exclusive unique peptides were successfully identified and mapped
to the Dnmt1 amino acid sequence accounting for a 54% coverage (Figure 24C-D), while only 9
exclusive unique peptides were successfully identified in the cleaved N-terminal Flag-fragment, which
correspond to 8% coverage of Dnmt1 amino acid sequence (Figure 24C and E). The most downstream
peptide mapped from the cleaved N-terminal Flag-fragment (SKEDPDREARPE) ended at Glu265 of
Dnmt1 (Figure 24E). Based on the sizes of the cleaved N-terminal fragment (~50 kDa) and the
remaining Dnmt1 protein product (~160 kDa), we estimated that the cleavage site is around residue 450.
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Interestingly, the N-terminal ~450-amino-acid region containing several conserved domains (Figure
23A). For example, this region contains the sequences required for the interaction with DMAP1,
Dnmt3a, Dnmt3b and the PRC2/Eed-Ezh2 complex. Of these, it has been suggested that the interaction
with DMAP1 regulates Dnmt1 stability, as the DMAP1-interaction domain (residues 1 to 120) is also not
present in the more stable DNMT1o isoform (53). Moreover, the missing N-terminal fragment from
intestinal Dnmt1 also contains the PBD region (residues 161 to 172), which mediates the interaction
between Dnmt1 and PCNA, and the NLS motif (residues 175 to 202) (8). Together, these results suggest
that the short intestinal Dnmt1 protein lacks a region that harbors important motifs required for the
interaction with proteins that play different regulatory functions such as interaction with the DNA
replication machinery, localization and stability.
Furthermore, the cleaved N-terminal fragment of intestinal Dnmt1 contains several sites that are
modified by different PTMs, most notably serine phosphorylation. In fact, phosphorylation of one of
these serine residues (Ser143 in human DNMT1, equivalent to Ser140 in mouse Dnmt1) by Akt1 has
been implicated in Dnmt1 stabilization, while methylation of the adjacent lysine residue (Lys142 in
human DNMT1, Lys139 in mouse Dnmt1) by Set7/9 was associated with Dnmt1 degradation (211). In
addition, this cleaved fragment might also be required for the homodimerization of Dnmt1, which has
been reported to be mediated by head to head interaction of the N-terminal domains (212).
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See Figure 24 legend in next page.
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Figure 24: Mouse intestinal Dnmt1 protein product was generated by an endoproteolytic cleavage event.
A. Western blot of Dnmt1 protein products in extracts from purified intestinal crypts, intestine and colon,
compared to full-length Dnmt1 transfected into Dnmt1 KO mESCs as control. Arrows indicate the
position of Flag-Dnmt1 full-length (F.L.), short Dnmt1 and the N-terminal protein fragment. B. Flag
immunoprecipitation of intestinal Flag-Dnmt1 full-length uncleaved protein and cleaved Flag-N-terminal
protein fragment from intestinal crypts purified from Flag-Dnmt1 KI homozygous mouse. Gel was
stained with Coomasie Blue and the indicated protein bands were excised and analyzed by mass
spectrometry (MS). C. Protein sequence coverage by the MS analysis of both the Flag-Dnmt1 uncleaved
protein and the cleaved N-terminal protein fragment. D. Peptides detected in MS analysis (yellow) from
the full-length Flag-Dnmt1 uncleaved protein mapped to Flag-Dnmt1 knock-in amino acid sequence. E.
Peptides detected in MS analysis (yellow) from the cleaved N-terminal protein fragment mapped to FlagDnmt1 knock-in amino acid sequence.
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Global DNA methylation in intestine is not significantly different from that in other tissues.
The results described above suggest that the N-terminal cleavage of intestinal Dnmt1 might have
regulatory implications, as the cleaved fragment contains important regulatory domains that mediate
protein interactions and specific residues that are likely subjected to PTMs with regulatory functions.
Therefore, it is reasonable to hypothesize that intestinal short Dnmt1 protein could have different DNA
methylation activity. To test this hypothesis, we first analyzed DNA methylation levels using the
methylation-sensitive restriction enzymes HpaII and MaeII, followed by southern blot hybridization at
the centromeric and pericentric heterochromatic regions of minor satellite repeats and major satellite
repeats, respectively. We compared DNA purified from intestine, colon, brain and liver tissues and from
purified intestinal crypts with Dnmt1 KO or wild-type mESCs as controls. DNA methylation analysis at
minor satellite repeats failed to detect any significant difference in DNA methylation levels in mouse
tissues, purified crypts, and mESCs (Figure 25A). In contrast, when DNA methylation levels at major
satellite repeats were analyzed, we detected a lower level of DNA methylation in the colon tissue sample,
while no difference was observed for the rest of the tissues (Figure 25B). We further analyzed total levels
of DNA methylation by dot blot analysis using 5mC specific antibody, in this case comparing DNA
samples obtained from brain, lung, liver, intestine, colon and ovary. Our results showed that DNA
methylation was slightly higher in intestine compared to the rest of the tissues, and that the lowest levels
of DNA methylation were detected in colon (Figure 25C), as similarly observed with major satellite
repeats methylation analysis.
Despite this interesting observation, more quantitative and specific experiments, such as
quantification of total 5mC by LC-MS/MS and genome-wide DNA methylation analysis by WGBS,
would confirm whether DNA methylation is significantly different in intestine compared to other tissues.
If this turn out to be the case, it might be possible that intestinal Dnmt1 acquires enhanced stability
through the cleavage of its N-terminal, similarly as the more stable Dnmt1o that lacks the first 118 amino
acids including the DMAP1 interacting domain (53). However, this hypothesis requires further
investigation.
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In summary, our finding that Dnmt1 is post-translationally processed in intestine is intriguing but
preliminary. Determining the molecular mechanism and biological significance of this cleavage event
would contribute to the understanding of the regulation of DNA methylation in intestinal tissue and the
role that this plays in maintaining intestinal epithelial homeostasis and regeneration.

99

Figure 25: DNA methylation analysis in mouse tissues.
DNA methylation analysis by digestion with methylation-sensitive enzymes and southern blot
hybridization for the minor satellite repeats (A) or major satellite repeats (B), in mouse tissues compared
to mESCs. Dnmt1 KO and wild-type mESC were used as controls. C. Analysis of total DNA methylation
levels by dot blot using 5mC specific antibody in different mouse tissues. Total DNA was stained with
Sytox Green Dye as loading control.
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CHAPTER 6: DISCUSSION

A complex network of different types of epigenetic mechanisms control the structure and
functions of chromatin that is fundamental for multiple biological processes. DNA methylation, which is
present in many eukaryotic organisms, is an important component of the network (196). In mammals,
DNA methylation is essential for a variety of biological functions, and its dysregulation plays major roles
in the development of multiple human diseases (3, 165). Since the discovery of DNA methylation more
than 60 years ago (1), extensive research in this epigenetic modification has elucidated most of its
functions (5). However, many aspects of the regulation of DNA methylation remain poorly understood.
The regulation of DNA methylation is complex, which occurs at different levels, including the
production of multiple DNMT isoforms. For example, as described earlier in section 1.2, DNMT3A has
two major isoforms, the full-length DNMT3A1 that is ubiquitously expressed at low levels in most
somatic cells, and a shorter isoform known as DNMT3A2 (Figure 2), which is highly expressed in
mESCs and germ cells. DNMT3A1 is highly enriched and tightly associated with heterochromatin, and
DNMT3A2 is more widely distributed on and less tightly bound to chromatin (213). In the case of the
DNMT3B, alternative splicing generates more than 30 isoforms, many of which lack catalytic activity
but might play regulatory roles (26). For instance, mESCs mainly express the full-length catalytically
active isoform DNMT3B1 and the inactive DNMT3B6, while somatic cells mainly express DNMT3B2
and DNMT3B3, which are active and inactive isoforms, respectively (18, 213). In addition, three
different isoforms of DNMT3L are expressed from cell-specific promoters at different developmental
stages (180). Similarly, as described in detail in section 1.3, DNMT1 also express two major cell-specific
isoforms, the full-length DNMT1 is expressed in somatic cells, while the shorter isoform DNMT1o is
produced exclusively in oocytes (Figure 2) (8). In Chapter 5 of this dissertation, I described the
identification of a new DNMT1 protein product, which is specifically present in mouse intestine. In clear
contrast to the other known DNMTs isoforms that are generated by alternative splicing or different
promoter usage, this new DNMT1 protein is generated by cleavage of the N-terminal region of the fulllength DNMT1 in intestinal stem cells (ISCs) (Figure 24). Endoproteolytic cleavage is a posttranslational
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processing event that regulates the activity of a great number of proteins involved in multiple
physiological functions, including signal transduction pathways or activation of apoptosis (214, 215). For
example, in the Notch signaling pathway, the cleavage of the intracellular domain of the receptor is
required for its nuclear translocation, where it binds to transcription factors and activates gene expression
(214). In addition, proteolytic cleavage is also used to activate caspases from its pro-caspase inactive
form, which in turn are responsible for the cleavage of multiple substrates to trigger apoptosis (215). To
the best of my knowledge, the cleavage of the N-terminal region of DNMT1 is the first example of this
kind of processing occurring in proteins involved in DNA methylation. Although the precise point of
cleavage remains to be determined, the size of the cleaved fragment suggests that the resultant DNMT1
protein product, like Dnmt1o, would lack the functional domain that mediates the interaction with
DMAP1. Dnmt1o has been shown to be more stable than the full-length Dnmt1 (53). It is therefore
possible that this cleavage event is functionally important for ISCs, which are actively proliferating,
unlike most adult stem cells that are generally quiescent. However, further biochemical, cellular and
genetic studies are required to determine the biological role and functional significance of this event.
DNA methylation can also be regulated by DNMT-interacting proteins and cofactors. For
instance, as described in section 1.2, in vitro studies demonstrate that DNMT3L serves as a cofactor for
both DNMT3A and DNMT3B, as it enhances their catalytic activity to similar extent (166-168).
However, the in vivo function of DNMT3L seems to be very different, as genetic studies in mice showed
that Dnmt3L deletion results in infertility (42, 44, 45), while this phenotype was only recapitulated by the
conditional deletion of Dnmt3a, but not Dnmt3b, in the germ line (35). These genetic evidences suggest
that the functions of DNMT3L in vivo are more likely associated with DNMT3A activity, rather than
DNMT3B activity. What determines the functional specificity of Dnmt3L is not well understood. In
Chapter 3 of this dissertation, I addressed this issue using mESCs, which express high levels of
DNMT3A, DNMT3B and DNMT3L, consistent with the high rate of de novo DNA methylation
observed in these cells (32). By genome-wide DNA methylation analysis, I found that a significant
fraction of the genome is hypomethylated in DNMT3L-deficient mESCs, with the majority of
hypomethylated CpG sites being DNMT3A targets (Figure 8). Importantly, I found that DNMT3L is
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critical for DNMT3A (especially DNMT3A2) protein stability through direct interaction and the
formation of the DNMT3L-DNMT3A2 complex (Figure 12). Therefore, in the absence of DNMT3L,
DNMT3A2 protein becomes unstable and is rapidly degraded, leading to DNA hypomethylation at
DNMT3A-specific loci. These findings, described in Chapter 3, uncover a new role for DNMT3L in the
regulation of DNMT3A function, which provides a plausible explanation for the functional specificity of
DNMT3L in vivo (Figure 13C). My results also confirmed that DNMT3L is predominantly a positive
regulator of de novo methylation, contrary to a recent report showing that DNMT3L regulates DNA
methylation positively or negatively, depending on genomic regions, in mESCs (49).
While DNMT3L is an important regulator of de novo DNA methylation, UHRF1 is essential for
maintenance DNA methylation by directing DNMT1 to hemi-methylated CpG sites generated during
DNA replication (50, 51). Multiple studies have explored the regulation of UHRF1 functions in the
modulation of DNA methylation using mESCs as a model system. For example, a recent study from our
laboratory, which I contributed to, showed that UHRF1 degradation is responsible for global DNA
hypomethylation in a small population, known as 2C-like mESCs, and that this event is essential for the
maintenance of telomere homeostasis and long-term self-renewal of mESCs (148). Another study
showed that mESCs cultured in 2i medium, which maintains mESCs in the ground naïve state (216),
show global DNA hypomethylation due, at least in part, to reduction of UHRF1 at the protein level
(217). The role of UHRF1 in DNA methylation is complex, as it can act either as a positive regulator by
serving as a DNMT1 cofactor or as a negative regulator through its E3 ligase-mediated degradation of
UHRF1 itself and DNMT1. For instance, UHRF1 is frequently upregulated in cancer, and
overexpression of UHRF1 experimentally can induce global DNA hypomethylation and tumorigenesis
(109). Together, all these findings indicate that UHRF1 is a major point of regulation in inducing
changes in global DNA methylation during normal development and in diseases.
In Chapter 4 of this dissertation, I provided evidence that global DNA methylation can also be
altered by regulating UHRF1 chromatin association. UHRF1 has different domains that recognize
epigenetic modifications, which play critical roles in its regulation through a complex crosstalk between
DNA methylation and different histone modifications (196). Previous biochemical studies showed that
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the PHD finger of URHF1, which is slightly different from other PHD fingers that usually bind to
trimethylated lysine residues in histones (e.g. H3K4me3) (218), instead binds to unmodified H3R2, but
not methylated H3R2 (65). My work, described in Chapter 4, extended the previous finding by
demonstrating that H3R2 methylation has a major effect on DNA methylation. Specifically, I showed
that PRMT6, an enzyme responsible for H3R2me2a, negatively regulates global DNA methylation by
impairing the recruitment of UHRF1 to chromatin. My finding uncovers a functional and mechanistic
link between histone arginine methylation and DNA methylation, an area we are largely ignorant about,
unlike the crosstalk between histone lysine methylation and DNA methylation, which has been well
established (196). Notably, PRMT6 is highly overexpressed in cancer cells, which also exhibit global
DNA hypomethylation as a characteristic epigenetic feature (4, 113). Based on the evidence, I further
explored the connection between these two molecular alterations in cancer cells. The results obtained
indicate that PRMT6 is indeed upregulated in both cancer cell lines and in many primary tumor samples,
and that this upregulation correlates with global DNA hypomethylation in cancer (Figure 18).
Importantly, I was also able to demonstrate that the effect of PRMT6 on DNA methylation is reversible
in cancer cells, as depletion of PRMT6 protein or inhibition of its enzymatic activity leads to restoration
of DNA methylation levels in MCF7 cells, a breast cancer cell line with high expression of PRMT6
(Figure 20). This finding has important translational implications, as it raises the possibility of targeting
PRMT6 for cancer therapy. In addition, recent studies showed that the combination of the DNMT
inhibitor 5-azacitidine (5-Aza) with immune checkpoint blockade therapy (anti-CTLA-4 and anti-PD-L1)
have important synergistic anti-tumor effects (219-226). My findings demonstrate that similarly to 5-aza,
PRMT6 overexpression causes global DNA hypomethylation in cancer cells. This can be advantageous
to clinicians, as the effect of DNA hypomethylation is specifically restricted to cancer cells, unlike 5-aza
that is delivered systemically and has important side effects. It will be interesting to explore whether
tumors with PRMT6 upregulation are more sensitive to immune checkpoint therapy and whether PRMT6
levels can be used for patient stratification for the choice of therapies.

104

In summary, my work led to the following key conclusions: i. DNMT3L is a positive regulator
of de novo DNA methylation in mESCs that mainly affects DNMT3A target regions; ii. The functional
specificity of DNMT3L is largely conferred by its role in stabilizing DNMT3A2 protein; iii. PRMT6
negatively regulates maintenance DNA methylation by impairing the recruitment of the UHRF1DNMT1 complex to chromatin; iv. PRMT6 upregulation contributes to global DNA hypomethylation in
cancer cells; v. PRMT6-induced DNA hypomethylation is reversible in cancer cells; and vi. Intestinal
stem cells produce a shorter DNMT1 protein due to endoproteolytic cleavage. These findings expand the
knowledge on the regulation of DNA methylation in mammalian development and cancer.

Future directions
The research findings described in this dissertation suggest important potential avenues for
further research in the future. For instance, the presence of DNMT3L and DNMT3A is essential for the
establishment of genomic imprints in germ cells, as their deletion in these cells show almost identical
phenotypes (35, 42, 44, 45). Given its ability to stimulate DNMT3A activity in vitro, DNMT3L is
generally assumed to function primarily as a catalytic cofactor of DNMT3A. Based on my findings
reported in Chapter 3, it is likely that DNMT3L plays a critical role in stabilizing DNMT3A2 in germ
cells as well (DNMT3A2 is the major DNMT3A isoform in the germ line). It will be interesting to
examine the levels of DNMT3A2 in prospermatogonia and growing oocytes in DNMT3L KO mice and
determine the significance of DNMT3A2 degradation (if proved true) in the phenotypes associated with
DNMT3L deficiency, including the failure to establish germ line imprints.
It is well established that various epigenetic mechanisms function cooperatively in regulating
chromatin structure and functions. The crosstalk between arginine methylation and DNA methylation has
been an understudied area. My work described in Chapter 4 indicates that PRMT6-mediated H3R2me2a
is an epigenetic modification that negatively regulates DNA methylation and that dysregulation of this
mechanism contributes to global DNA hypomethylation in cancer cells. Many questions remain to be
answered. For example, it will be important to determine whether the mechanism is relevant in the
regulation of DNA methylation in normal developmental and cellular processes. Given its dramatic
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effect on global DNA methylation, it will be particularly interesting to investigate whether PRMT6
expression and function are dynamically regulated and whether it plays a critical role in epigenetic
reprogramming events during early embryogenesis and in germ cells.
Moreover, global DNA hypomethylation is a common epigenetic alteration observed in cancer
cells that has been associated with tumorigenesis (4). In addition, PRMT6 is frequently overexpressed in
cancer cells, and several studies propose multiple roles implicating it in malignant transformation (113).
In Chapter 4, I described the identification of a correlation between PRMT6 upregulation and global
DNA hypomethylation in cancer cells, and provided evidence for the molecular mechanism involved.
However, it remains to be investigated whether PRMT6-dependent DNA hypomethylation plays a major
role in the formation and/or progression of tumors. The answer to this question could advance our
understanding of the importance of DNA methylation in oncogenesis and provide further information
regarding the relevance of targeting this mechanism for therapeutic purposes.
Finally, in Chapter 5 of this dissertation, I described the finding of a short DNMT1 protein
product present specifically in intestinal stem cells, which results from an endoproteolytic cleavage
event. However, multiple issues remain to be addressed. The most important is to elucidate the biological
significance of this event, together with the elucidation of the molecular mechanisms underlying this
process (e.g. the enzyme(s) involved). Intestinal stem cells are very important to maintain tissue
homeostasis in the gut, and they have been implicated in the development of colon cancer. Determining
the function, mechanism and significance of this unique DNMT1 protein product could shed light on the
functions of intestinal stem cells.
Exploration of these research questions would further contribute to our understanding of the
regulation of DNA methylation in mammalian development and human diseases.
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